Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - CardioGenics Holdings Inc.v308630_ex32-1.htm
EX-31.1 - EXHIBIT 31.1 - CardioGenics Holdings Inc.v308630_ex31-1.htm
EX-31.2 - EXHIBIT 31.2 - CardioGenics Holdings Inc.v308630_ex31-2.htm
EX-23.3 - EXHIBIT 23.3 - CardioGenics Holdings Inc.v308630_ex23-3.htm
EX-23.2 - EXHIBIT 23.2 - CardioGenics Holdings Inc.v308630_ex23-2.htm
EX-23.1 - EXHIBIT 23.1 - CardioGenics Holdings Inc.v308630_ex23-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 10-K/A

Amendment No. 2

 

 

  

  þ

Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the fiscal year ended October 31, 2011

 

OR

 

  ¨

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from __________ to __________.

 

Commission file number: 000-28761

 

CARDIOGENICS HOLDINGS INC.

(Exact name of registrant as specified in its charter)

 

Nevada 88-0380546
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)

 

6295 Northam Drive, Unit 8, Mississauga, Ontario L4V 1W8

(Address of principal executive offices) (Zip code)

(905) 673-8501

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:  None

 

Securities registered pursuant to Section 12(g) of the Act:

Common Stock—$0.00001 par value

Series 2 Class B Common Stock—$0.00001 par value

Series 3 Class B Common Stock—$0.00001 par value

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes ¨  No þ

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes ¨  No þ.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ  No ¨.

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes þ No ¨.

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. þ

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer or a small.  See definition of “large accelerated filer, accelerated filer and smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ (Do Smaller reporting company
    not check if smaller reporting þ
    company)  

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes ¨  No þ.

 

The aggregate market value of the registrant’s voting and non-voting common stock held by non-affiliates on January 11, 2012 (based on the closing stock price on the OTC Bulletin Board) on such date was approximately $9,371,179.

 

As of January 11, 2012 the Registrant had the following number of shares of its capital stock outstanding: 31,237,262 shares of Common Stock and 1 share of Series 1 Preferred Voting Stock, par value $0.0001, representing 14 exchangeable shares of the Registrant’s subsidiary, CardioGenics ExchangeCo Inc., which are exchangeable into 24,388,908 shares of the Registrant’s Common Stock.

 



 
 

  

EXPLANATORY NOTE

  

This Amendment to our annual report on Form 10-K/A is being filed in order to restate:

 

.our consolidated balance sheet as of October 31, 2011 by decreasing amounts reported in deposits and prepaid expenses, prepaid consulting contract, total assets, total equity attributable to CardioGenics Holdings Inc., total equity and total liabilities and equity and increasing amounts reported in government grants and investment tax credits receivable, accounts payable and accrued expenses, deficit accumulated during development stage, accumulated other comprehensive loss, and non-controlling interest.

 

.our consolidated statement of operations for the year ended October 31, 2011 by decreasing amounts reported in research and product development, net of investment tax credits, and increasing general and administrative expenses, total operating expenses, operating loss, loss from continuing operations before income tax, net loss, net loss attributed to non-controlling interest and net loss attributed to CardioGenics Holdings Inc.

 

During the preparation of the January 31, 2012 interim consolidated financial statements, the Company determined that the accounting for the issuance of common stock and warrants in the year ended October 31, 2011 required restatement. The Company also determined that the recording of certain tax related income and expenses required restatement.

 

As a result of these restatements, amounts in our consolidated balance sheet, statement of operations, statement of cash flows and equity for the year ended October 31, 2011 have been corrected. This restatement also resulted in changes to notes 8 and 9 to the consolidated financial statements. Cash flow has been restated to reflect classification errors resulting in an increase in cash from operating activities of $111,927.

 

The restatement relates to the following:

 

a)in September 2011 we entered into consulting contracts covering a period of eighteen months, compensation for which included the issuance of common stock and fully vested warrants. The Company determined that the fair value of the compensation was $2.1 million. Based on our initial evaluation of the relevant accounting guidance, the Company recorded the fair value as an asset as part of a prepaid expense in 2011 and began amortizing this balance to General and Administrative expense over an eighteen month period. The offset to the prepaid expense was recorded as Additional Paid-in Capital. The Company has subsequently determined that the entire fair value of the compensation for these contracts should have been expensed immediately rather than recorded as an asset.  In order to correct this error, the Company reduced the current portion of Deposits and Prepaid Expenses by $1,309,296 and Prepaid Consulting Contract by $567,015 as at October 31, 2011, expensed the fair value of these contracts of $1,869,660 as part of General and Administrative expenses in the year ended October 31, 2011 and recorded a reduction in Currency Translation Adjustment of $6,651;
b)the Company determined that a Government Grant and Investment Tax Credit receivable relating to investment tax credits under the scientific research and experimental development auspices of the Canadian income tax act in the amount of approximately $187,497 had formerly not been recorded. In order to correct this error, the Company increased Government Grants and Investment Tax Credits Receivable and reduced General and Administrative expenses as at and for the year ended October 31, 2011; and,
c)the Company determined that potential tax penalties in the amount of $180,000 related to the late filing of certain tax returns with the Internal Revenue Service had formerly not been recorded.  In order to correct this error, the Company increased Accounts Payable and Accrued Expenses and General and Administrative expenses as at and for the year ended October 31, 2011.

 

 
 

  

A summary of the effects of this restatement to our financial statements included within this Amendment on Form 10-K/A in presented at Note 2, “Restatement of Financial Statements”.

 

This Amendment amends Part II, Items 6,7,8 and 9A, and Part IV, Item 15 of the Annual Report on Form 10-K for the year ended October 31, 2011. This Amendment continues to reflect circumstances as of the date of the original filing of the Annual Report on Form 10-K for the year ended October 31, 2011 and we have not updated the disclosures contained herein to reflect events that occurred at a later date, except for items related to the restatement or where otherwise indicated.

 

 
 

 

CARDIOGENICS HOLDINGS INC.

 

ANNUAL REPORT ON FORM 10-K

 

FOR THE FISCAL YEAR ENDED OCTOBER 31, 2011

 

TABLE OF CONTENTS

 

  Page
   
Part I 1
   
Item 1. Business 1
Item 1A. Risk Factors 12
Item 1B. Unresolved Staff Comments 19
Item 2. Properties 19
Item 3. Legal Proceedings 19
Item 4. (Removed and Reserved) 20
   
Part II 21
   
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Securities 21
Item 6. Selected Financial Data 23
Item 7. Management’s Discussion and Analysis or Plan of Operation 23
Item7A. Quantitive and Qualitative Disclosure about Market Risk 28
Item 8. Financial Statements and Supplementary Data 28
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 28
Item 9A. Controls and Procedures 28
Item 9B. Other Information 29
   
Part III 29
   
Item 10. Directors, Executive Officers and Corporate Governance 29
Item 11. Executive Compensation 31
Item 12. Security Ownership of Certain Beneficial Owners and Related Stockholder Matters 33
Item 13. Certain Relationships and Related Transactions, and Director Independence 34
Item 14. Principal Accounting Fees and Services 35
   
Part IV 36
   
Item 15. Exhibits, Financial Statement Schedules 36

 

 
 

 

PART I

 

ITEM 1.  BUSINESS

 

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  Such statements are based upon current expectations that involve risks and uncertainties.  Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements.  Words such as “may,” “will,” “should,” “estimates,” “predicts,” “potential,” “continue,” “strategy,” “believes,” “anticipates,” “plans,” “expects,” “intends” and similar expressions are intended to identify forward-looking statements.  Our discussions relating to our liquidity and capital resources, our business strategy, our competition, and the future of our market segment, our acquisition of CardioGenics Inc., an Ontario Canada corporation (“CardioGenics”), among others, contain such statements.  Our actual results and the timing of certain events may differ significantly from the results discussed in the forward-looking statements.

 

Our forward-looking statements in this Annual Report on Form 10-K are based on management’s current views and assumptions regarding future events and speak only as of their dates.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.  Unless the context requires otherwise, the terms “we,” “us” and “our” refer to CardioGenics Holdings Inc., our predecessors and subsidiaries. Our acquisition of CardioGenics as discussed in this Annual Report on Form 10-K is sometimes referred to as the “CardioGenics Acquisition.”

 

OVERVIEW

 

Prior to the CardioGenics Acquisition, our primary business was providing financial and investment information to the investment community which we had been doing since 1989. 

 

In July 2009, we consummated the CardioGenics Acquisition and the main focus of our business switched from offering our customers fee-based financial information to the development of products targeting the immunoassay segment of the point-of-care in vitro diagnostic (“IVD”) testing market. See “—Our Strategy—Acquisition of CardioGenics.”  In order to better reflect the new focus of our business, we changed our name to CardioGenics Holdings Inc. in October 2009.

 

We are a Nevada corporation. Our address is 6295 Northam Drive, Unit 8, Mississauga, Ontario, Canada L4V 1W8, and our telephone number is 905-673-8501.

 

COMPANY BACKGROUND

 

JagNotes, Inc.

 

We have been providing financial information to the investment community since 1989. In May 1999, we began offering our services on a subscription fee basis to the general public for the first time through our website at jagnotes.com. Through our website and our traditional fax-based service, we offer timely financial data, reports and commentary.

 

Our online services currently consist of a subscription-based service that offers two specific products, the JAGNotes (Upgrade/Downgrade) Report and the Rumor Room, providing timely market reports, including breaking news and potentially market moving information. We currently derive revenues primarily from the sale of subscriptions.

 

From 1989 to 1992, we operated as an unincorporated business entity. In 1992, we incorporated in the State of New Jersey as New Jag, Inc. On December 14, 1993, JagNotes, Inc. merged with and into New Jag Inc., and we changed our name to JagNotes, Inc. We operated as JagNotes, Inc. until March 1999 when we were acquired by Professional Perceptions, Inc., a Nevada corporation, which subsequently changed our name to JagNotes.com Inc.

 

Until 1999, we targeted only a limited audience of financial professionals and did not engage in organized sales and marketing efforts. In 1999, we decided to change focus by expanding onto the Internet and targeting retail subscribers with the hope of expanding our subscriber base and business. 

 

1
 

 

We undertook a corporate reorganization in January 2002 in order to distinguish and better manage separate areas of business. On January 4, 2002, we formed JAG Media LLC, a Delaware limited liability company and wholly-owned subsidiary. The assets and liabilities of our current fax and Internet subscription business were transferred to JAG Media LLC. In order to better reflect the overall business in which we expected to engage and the corporate structure we intended to use to conduct that business, we changed our name from JagNotes.com Inc. to JAG Media Holdings, Inc. effective April 8, 2002.

 

On November 24, 2004, through one of our subsidiaries, Pixaya (UK) Limited (“Pixaya”), we purchased certain development stage software products and related assets in the United Kingdom from TComm Limited, a company organized in the United Kingdom. We subsequently changed the name of our subsidiary, JAG Media LLC, to Pixaya LLC in order to better reflect its role as owner of Pixaya and primary provider of support for our Pixaya products in the United States. Due to cash constraints, we ceased financing development and marketing by Pixaya of our SurvayaCam product, a mobile surveillance system which streams live video in real time from the point of use back to a control center and, if desired, to other locations. To date, we have only made minimal sales of SurvayaCam as part of our prior marketing and distribution efforts.

 

In light of the difficulties we encountered in growing our JAG Notes subscription business and Pixaya business, we began seeking merger and acquisition candidates, in related and unrelated lines of businesses, to augment our current business. On July 31, 2009, we completed the acquisition of CardioGenics, a developer of products targeting the immunoassay segment of the Point-of-Care IVD testing market, based in Ontario, Canada. See “—Our Acquisition of CardioGenics.” On February 11, 2010 we sold our Pixaya LLC subsidiary, and its related JAG Notes subscription and Pixaya businesses, since we believe it would be more beneficial for our resources to be devoted solely to the development and commercialization of our core CardioGenics products.

 

CardioGenics Inc.

 

CardioGenics was founded in Toronto, Canada in 1997 by Dr. Yahia Gawad to develop technology and products targeting the immunoassay segment of the IVD testing market. These include:

 

  § The QL Care Analyzer (the “QLCA”), a state-of-the-art proprietary Point-of-Care (“POC”) immunoassay analyzer;

 

  § A series of immunoassay tests to detect cardiac markers (the “Cardiovascular Tests”); and,

 

  § Paramagnetic beads developed through its proprietary method, which improves their light collection (the “Beads”).

 

OUR INDUSTRY

 

CardioGenics IVD POC Testing Markets

 

IVD Market

 

In vitro diagnostics (IVD) refers to testing that aims for the identification of disease states outside the body, using samples such as body fluids (blood, urine) and tissues (biopsies and tissue sections). The IVD is a well established market, offering essential products (tests, components and machinery) used by physicians and clinical chemistry personnel to assess disease conditions. The world market for IVD is estimated at $42 billion in 2007 and is expected to grow 6% annually to $56.3 billion by 20121. North America, Europe, Japan and Western Europe currently make up 81% of the total IVD market, and this is expected to decrease to 76% by 2012 as China and India become more significant players in the IVD market. Sales of IVD products in emerging economies in Latin America and Eastern Europe are expected to grow from 4% of the market in 2007 to 5% in 2012. Overall, sales growth of IVD products in emerging markets will account for 10-20% annual growth in the IVD market, while the developed world will see annual growth of 3-6%.2



1 This includes all laboratory, hospital-based products and OTC products, according to Kalorama Information, The Worldwide Market for In Vitro Diagnostics Tests, 6th Edition, June 2008

2 Kalorama Information, The Worldwide Market for In Vitro Diagnostics Tests, 6th Edition, June 2008, p3

2
 

 

The following table summarizes the market size and projections of the IVD market and the sub-sectors where our products will compete:

 

Product   2007     2008     2009     2010     2011  
IVD  (billions)   $ 42.1     $ 44.5     $ 47.1     $ 49.1     $ 52.9  
Immunoassay Testing (billions)     4.185       4.435       4.695       4.975       5.260  
POC Testing (billions)     1.625       1.715       1.815       1.910       2.02  
Cardiac Marker Tests (millions)     425       471.75       523.64       581.24       645.17  

 

In 2007, 16 top tier IVD companies occupied 78% of the global market ($32 billion).  Since 2005, there has been a trend toward consolidation at all levels of the IVD market.  In 2007, three top tier companies, DPC, Dade Behring and Bayer Diagnostics, merged to become Siemens Medical Diagnostics.

 

Immunoassay Market

 

The 2007 world market for all immunoassays excluding infectious diseases is estimated at $4,185 million3, and by 2012 the market is projected to grow by 6% annually to reach $5,605 million worldwide. Immunoassays sales for cardiac markers were $785 million in 2007, or 12% of market, and this is expected to increase to $1,050 million (12%) by 20124. The following Table illustrates the relationships between the top IVD companies and sales of IVD products.

 

Revenue History of Leading Immunoassay Vendors, $ million 2005-20075

 

    2007     2006     2005  
Abbott Diagnostics     2,100       1,900       1,800  
Siemens/Dade Behring     825       785       750  
Siemens/Bayer     750       714       680  
Beckman Coulter     596       484       402  
Siemens/DPC     595       517       473  
Roche     575       509       450  
bioMérieux     363       362       353  
Fujirebio     299       277       279  
Ortho     200       190       160  
TOTAL     6,303       5,738       5,347  

 

Immunoassay testing segment of the IVD market is characterized by:

 

  · Expanding opportunities after completion of the human genome project.

 

  · Demand for automated and sensitive POC immunoassay analyzers.

 

  · Search for an ideal POC platform.

 

 

3 $6.685 million including infectious diseases 

4 Kalorama Information, The Worldwide Market for In Vitro Diagnostics Tests, 6th Edition, June 2008, p401 

5 Estimated. Kalorama Information, The Worldwide Market for In Vitro Diagnostics Tests, 6th Edition, June 2008, p402

3
 

 

  · Increased mergers and acquisition among top tier IVD companies to achieve more complete product lines

 

  · Greater cooperation between test developers and top tier IVD companies.

 

Over the next 5-10 years, the immunoassay business will see:

 

  · The continued automation of routine immunoassays – thyroid, anemia, fertility, therapeutic drug monitoring and drugs of abuse; and

 

  · More new assays and test categories for disease risk evaluation.6

 

Point-Of-Care (POC) Testing Market

 

Point Of Care (POC) testing refers to a laboratory assay that can be performed outside of a centralized facility, with results available within minutes. POC testing is divided into personal use tests, such as pregnancy tests, and professional use tests, that are administered in a physician’s office or hospital emergency ward. Our tests will compete in the professional use testing market sector.

 

The market for professional7 POC immunoassays is estimated at $1,625 million in 2007 and with the 14% projected growth, this market will reach $2,770 million in 2012. It is anticipated that most of the growth will come from increased use of cardiac markers and new assays for cancer markers and diabetes/cardiac disease markers. The market for professional POC tests for cardiac markers is estimated at $425 million in 2007 (11%) and this is expected to increase to $850 million (15%) by 2012.7

 

There is a wide perception that POC tests are more expensive than lab-based tests and that patient test results are lost to the historical record. There is also the perception that once the patient leaves the acute care area, the baseline POC tests done in that unit are of little value because the POC testing results do not correlate with lab-based systems.

 

Two critical characteristics are necessary for potential POC test products to become more prevalent; POC testing results must correlate with lab results and the POC devices must be more consistent and robust in delivering those results.

 

The impact of POC testing on improving patients’ care is clear and has been well documented. Further, the impact of POC testing on saving healthcare resources was also demonstrated by numerous agencies and institutions.

 

Cardiovascular Disease Testing Market

 

Cardiac markers are proteins released from heart muscle when it is damaged as a result of a heart attack (myocardial infarction), when the blood supply to part of the heart is interrupted. Physicians use cardiac markers in two ways – to diagnose a cardiac event in a hospital emergency room or within the hospital or to evaluate a risk of a cardiovascular event occurring. The routine markers of myocardial infarction – CK-MB, troponin and myoglobin and recently BNP are used in the acute care and tests such as cholesterol are used to evaluate risk.

 

The world market for cardiac markers is estimated at $740 million in 2007, and with projected annual growth of 5%, will reach $1,050 million in 2012.

 

Until recently, Troponin and CK-MB were the lead cardiac markers. Brain Natriuetic Pepetide (BNP) was recently introduced to differentiate between a myocardial infarction and heart failure. A number of companies are focused on developing new cardiac markers.

 

Magnetic Particles Market

 

Magnetic particles, or beads, are widely used as the solid phase for binding tests for automating and simplifying the methods for isolation and detection of biomolecules in both research and routine clinical laboratories. Eight of the top 10 IVD companies employ magnetic particles in their fully automated analyzers.

 

 

6 Kalorama Information, The Worldwide Market for In Vitro Diagnostics Tests, 6th Edition, June 2008 

7 Administered in a professional setting, i.e. not home tests.

4
 

 

An independent 2006 market research report, prepared for CardioGenics by Adventus Research Inc. (the “Adventus Report”) and sponsored by the National Research Council of Canada (NRC), estimated the market for magnetic beads for immunoassays and molecular diagnostics to be approximately $900 million (between $833 million and $1.3 billion). The report of market size did not include magnetic beads produced in-house by some of the IVD test manufacturers or beads produced for research applications. The Adventus Report was conducted using several methods, including interviews with leading particle-manufacturers and the end-users, published industry reports and data from leading IVD manufacturers.

 


 

As stated in the Adventus Report, according to Dynal, a leading magnetic beads manufacturer, the largest part of its Molecular Systems’ business is OEM sales of magnetic beads to IVD companies. Dynal stated that “the IVD market is very large, and still growing. However, the magnetic bead-based part of this market is growing at an even higher rate per year”.8 According to Dynal, immunoassays make up more than USD 4 billion of the IVD market, and magnetic beads are now the gold standard for immunoassay testing, as opposed to older technologies such as microtitre plate based tests. Nucleic acid testing makes up a smaller portion of the IVD market, USD 2 billion, but is fast growing. Magnetic beads are also the most common solid phase employed in this market.

 

Furthermore, according to Dynal, as stated in the Adventus Report, end-user business rather than OEM business (referred to as functionalized and naked beads markets respectively) goes to research and routine laboratories within Genomics, Expression Profiling and Proteomics. The market size for Genomics, including DNA and RNA extraction and purification products was USD 300 million in 2001 while the market size of Pharmacogenomics was estimated to be USD 2.3 billion in 2001.

 

As stated in the Adventus Report, according to Gen-Probe, which is a leading DNA clinical testing company, other markets that are employing magnetic beads as a solid phase are growing also. Further, magnetic particles are used for Separation of Microorganisms in Food and Water Testing and also for HLA testing for organ transplantation.

 

 

 

8  Adventus Report

 

5
 

 

 

Source:  Gen-Probe presentation- May 2006

 

OUR PRODUCTS

 

The CardioGenics Products

 

QL Care Analyzer

 

 

The QLCA represents a shift in the design of POC analyzers. The QLCA is a small, portable, stand-alone and completely automated point-of-care immunoassay analyzer. The QLCA has successfully miniaturized lab test technology, and combined it with a simplified mechanical design and proprietary triggering mechanism.

 

The QLCA uses a proprietary self-metering cartridge to perform immunoassay tests at the POC. Each cartridge is pre-loaded with our beads, which have been coated with specific bioluminescent proteins linked to the target marker. A drop of whole blood added to the Cartridge creates the chemiluminescent reaction needed to deliver sensitive and accurate test results. Operation of the QLCA does not require specialized training and testing can be completed in 15 minutes.

 

POC immunoassay analyzers are not new; however, none of the commercial analyzers can replicate the sensitivity and accuracy of a test done in a medical lab. The QLCA delivers the required laboratory sensitivity and accuracy. The QLCA employs chemical light generation or “chemiluminescence“ (“CL“), the same technology used in the medical labs. The QLCA uses a patented automated electronic process to trigger CL, which enhances light collection, speeds up marker binding and increases sensitivity.

 

We have rigorously tested the QLCA protocols and have compared our test results against medical laboratory test data. Based on these internal test results, we have consistently met or exceeded the sensitivity standards of medical laboratory immunoassay equipment.

 

6
 

 

Cardiovascular Tests

 

To support the use of the QLCA, we have developed four immunoassay tests designed to identify cardiac markers in the blood at the time of a heart attack.

 

Test

 

Description

Troponin I (TnI)   § TnI testing is the current routine testing for a heart attack.
    § TnI is a heart muscle protein, released in the bloodstream shortly after a heart attack (myocardial infarction or MI).
    § Current laboratory analyzers cannot detect TnI before 4-6 hours after the onset of symptoms, when TnI concentration in the blood reaches its detection threshold.
    § Our test will take only 15 minutes to deliver quantitative results, allowing physicians to obtain much more rapid results and therefore accelerate patient triage.
       
Plasminogen Activator Inhibitor Type-1 (PAI-1)   § This test will help to optimize the performance of a heart drug (“tPA” or tissue Plasminogen Activator), a clot buster used as the first line of therapy for MI patients.
    § This proprietary whole blood test will quantify PAI-1 levels within 15 minutes.
    § Forty percent of patients do not respond to tPA, a fact recognized only after the “golden hour” (the time period in which permanent heart damage can be prevented) has passed.
       
Heart Failure Risk Stratification (HFRS)   § We have discovered a family of related proteins that are released into the bloodstream during heart failure.
    § We are developing a proprietary test, the Heart Failure Risk Stratification or HFRS test to stratify the risk of death in patients with heart failure, thus permitting the initiation of appropriate therapy at an early stage.
       
Heart Failure Genomics Risk (HFGR)   § We are developing a proprietary HFGR test that predicts the response of heart failure patients to routinely administered drugs.
    § The need to measure the precise response to these drugs in a timely manner would minimize the trial and error methods now used by doctors to optimize drugs best suited to each patient.

 

These tests are designed to be administered in the diagnostic and management process of patients with heart disease. The full scope of our core technology, as well as the know-how we have developed respecting aspects of chemical entrapment in bioassays, are covered under our patent applications.

 

Upon receipt of FDA approval, we intend to market the QLCA and the Cardiovascular Tests through a major IVD distributor. We have initiated preliminary discussions with several of the Tier 1 IVD companies, and we anticipate that we will commence negotiations with one or more distribution partners before we receive FDA approval. In accordance with industry practice, we intend to enter into a license agreement with our distribution partner for the manufacture and distribution of our products.

 

7
 

 

Paramagnetic Beads

 

Medical laboratories widely use paramagnetic particles as a solid surface in heterogeneous immunoassay tests utilizing the process of phase separation done by eletromagnetic field.  Such tests involve the measurement of light generated on the surface area of paramagnetic beads coated with bio-organic material.

 


 

Our Beads represent a significant product advance. Most paramagnetic beads are made of iron oxide, and all are traditionally black or brown. We have developed a proprietary process that coats the beads with a layer of silver, making them white, and more sensitive to light. Our production process is also significantly less expensive than those used by our competitors. We have internally tested our Beads against all commercially available beads, and have found our silver-coated Beads to be five times more sensitive than traditional black or brown magnetic particles.

 

On January 19, 2009 CardioGenics Inc., one of our Canadian subsidiaries, entered into a Supply, Development & Distribution Agreement with Merck Chimie S.A.S. (“Merck Chimie”) (the “Merck Agreement”), pursuant to which CardioGenics is required to furnish Merck Chimie with certain quantities of CardioGenics’ proprietary silver-coated paramagnetic beads (the “CardioGenics Test Samples”), which Merck Chimie is then required to encapsulate, on a test-basis, using Merck Chimie’s proprietary encapsulation process. After Merck Chimie selects the best encapsulation process, Merck Chimie agreed to then establish the manufacturing parameters for the final encapsulated beads (the “Merck Encapsulated Beads”) and thereafter scale-up production for commercial distribution of the Merck Encapsulated Beads. Currently, Merck Chimie is still in the process of refining its encapsulation of the CardioGenics Test Samples.

 

Pursuant to the Merck Agreement, Merck Chimie has the exclusive right, for ten (10) years, to distribute the Merck Encapsulated Beads on a worldwide basis, with CardioGenics receiving 30% of the net sales proceeds of the Merck Encapsulated Beads and Merck receiving 70% of such net sales proceeds. Merck is responsible for manufacturing and distributing the Merck Encapsulated Beads.

 

In addition to the agreement with Merck Chimie, we have also entered into Materials Transfer Agreements (“MTA”) with two other major international beads distributors with respect to our proprietary magnetic beads. Under the first MTA, CardioGenics will furnish the distributor with its silver-coated magnetic beads for polymer coating by the distributor. In addition, the distributor will provide CardioGenics with their magnetized bead prototypes, which CardioGenics will then silver-coat with its proprietary silver-coating technology. Under the second MTA, CardioGenics will furnish the distributor with its silver-coated magnetic beads for polymer coating and subsequent testing and evaluation by the distributor. Upon completion of the testing process, CardioGenics and the distributors will evaluate the test results and determine whether to further pursue commercialization of the resulting products.

 

Since the CardioGenics business described above is now our primary business, we decided to sell our Pixaya LLC subsidiary, and its related JAG Notes subscription and Pixaya businesses, so we can focus our attention and resources exclusively on our primary CardioGenics business. The sale of our Pixaya subsidiary was completed on February 11, 2010.

 

OUR STRATEGY

 

The success of our business depends on our ability to obtain the requisite financing and be able to:

 

 

·

complete the development of our QLCA and our cardiovascular tests;

 

 

·

obtain FDA approval of our QLCA and the cardiovascular tests;

 

 

·

develop further tests that can be run on our QLCA;

 

 

·

commercialize our Beads.

 

We will require additional funds in order to implement our full business strategy. Accordingly, we will need to raise additional funds through public or private financing, strategic relationships or other arrangements. We do not anticipate generating any significant revenue until after our first cardiovascular test has been approved by the FDA and our Beads are commercialized by Merck Chimie pursuant to our agreement with them.

 

8
 

 

Since our strength is product development and innovation, our strategy is focused on exploiting this strength. In terms of product development and innovation, we employ our internal resources to develop our products through the various phases of development. We also rely on external service providers to supplement our internal talents in product development.

 

We will outsource product manufacturing. In terms of the QLCA, both the cartridge assembly as well as the analyzer assembly will be contracted out to different OEM providers with the facilities and expertise to deliver quality products. We will maintain a quality control process to ensure that the products meet the predetermined specifications.

 

Product marketing and distribution will by achieved through partnerships with global companies with wide reach. As we have done with our magnetic beads, the QLCA will be marketed by a third party through licensing and distribution agreements. Notwithstanding this strategy, we also intend to evaluate the feasibility of directly marketing our magnetic beads and QLCA to appropriate end-users and may use such direct marketing efforts to supplement the efforts of our distribution partner(s).

 

We are also focusing on protecting our intellectual property and know how though maintaining a patent filing process on a global basis as well as maintaining confidentiality agreements with our staff, employees and service providers under contractual agreements.

 

Although we believe in these strategies, goals and targets, we cannot guarantee that we will be successful in implementing them or that, even if implemented, they will be effective in creating a profitable business. In addition, we are dependent on having sufficient cash to carry out our strategies

 

Regulation

 

CardioGenics Products

 

Our QL Analyzer, Cartridge and Tests are classified as medical devices. Our beads are reagents of medical testing equipment. Accordingly, they are subject to a number of regulations in the jurisdictions where our products will be sold.

 

United States

 

The testing, production and sale of IVD products are subject to regulation by numerous state and federal government authorities, principally the FDA.

 

Pursuant to the U.S. Federal Food, Drug and Cosmetic Act (“FD&C Act”), the FDA regulates the preclinical and clinical testing, manufacture, labeling, distribution and promotion of medical devices.

 

Medical devices are classified into three categories, Class I, Class II or Class III. The classification of a device is based on the level of control necessary to assure the safety and effectiveness of the device. Generally, the complexity of the submission and the approval times are based on the regulatory class of the device. Device classification depends on the intended use and also the indications for use of the device. Classification is also based on the risk the device poses to the patient and/or the user. Class I devices include devices with the lowest risk, and Class III devices are those with the greatest risk. Class I devices are subject to general control, Class II devices are subject to general controls and special controls, and Class III devices are subject to general controls and must receive a Premarket Assessment or PMA by the FDA.

 

Before some Class I and most Class II devices can be introduced in the market, either the manufacturer or distributor of the device is required to follow the pre-market notification process described in section 510(k) of the FD&C Act. A 510(k) is a pre-marketing submission made to the FDA to demonstrate that the device to be marketed is as safe and effective, and is substantially equivalent to a legally marketed device. Applicants must compare their 510(k) device to one or more similar devices currently on the US market and support their claims for substantial equivalency. The FDA requires a rigorous demonstration of substantial equivalency. It generally takes three to six months from submission to obtain 510(k) clearance. If any device cleared through 510(k) is modified or enhanced, or if there is a change of use of the device, a new amended 510(k) application must be submitted. According to FDA regulations and our management team’s prior experiences with submissions of similar products, our QLCA and launch product (TnI) will be classified as a Class II device and will be subjected to the 510(K) process. Further, a second test product of ours (HFRS) will also be subjected to the same 510(K) process. As for both tests, predicate devices are commercially available.  For other test products, depending on the claims and with a prior agreement with the FDA, the submissions would be either a PMA or 510(K). We have not yet approached the FDA for that purpose.

 

9
 

 

Canada

 

Health Canada sets out the requirements governing the sale, importation and advertisement of medical devices. These regulations are intended to ensure that medical devices distributed in Canada are both safe and effective. We are also required to comply with certain procedures for the disposal of waste products under the Canadian Code of Practice for the Management of Biological Waste (the “Code”). We believe we are currently in compliance with all required Code provisions.

 

Europe

 

Our products will be subject to registration under the EU Medical Device Directives for in-vitro diagnostic products.

 

Other countries

 

Our products will be subject to the regulations of any country where they are sold, and we will make the necessary applications for approval on a country-by-country basis.

 

Competition

 

CardioGenics Competitors

 

Numerous companies provide Point Of Care (POC) products, many with cardiovascular test products. However, in terms of quantitative POC products, few companies operate in this space with marketed devices. These include:

 

  · Biosite Diagnostics Incorporated;

 

 

·

Response Biomedicals Corp.;

 

 

·

Roche POC division; and

 

 

·

i-Stat division of Abbott Diagnostics

 

The first 3 companies employ fluorescence measurements in their platforms, while i-Stat employs electrochemical testing. We believe that our technology and products in development will offer superior products to the POC market. None of the above companies offer chemiluminescence in its platform, a technology that is well-recognized for its superiority as evidenced by its dominance in the laboratory testing market. We believe that harnessing chemiluminescence in our QLCA will fulfill the clinical demands for fast and accurate quantitative results at patient bedsides.

 

Research and Development

 

Our efforts are focused on the development of our QLCA and our cardiovascular tests and the commercialization of our beads. Over the years 2010 and 2011 we incurred expenses of $605,658 and $613,504 respectively on those efforts.

 

Website Technical Information

 

Our CardioGenics website (www.cardiogenics.com) is maintained by us internally and is hosted by DreamHost, which has hosting facilities located in Brea, California.

 

Employees

 

As of October 31, 2010, we had ten (10) employees. Of those employees, only Yahia Gawad, our Chief Executive Officer, has an employment agreement with the Company.

 

Acquisition of CardioGenics

 

On July 31, 2009 we completed the acquisition of CardioGenics by CardioGenics ExchangeCo Inc. (“ExchangeCo”), our Ontario, Canada subsidiary, pursuant to the terms of a Share Purchase Agreement dated May 22, 2009 among ExchangeCo, JAG Media Holdings, Inc., CardioGenics and CardioGenics’ principal stockholder, Yahia Gawad (the “Share Purchase Agreement”). CardioGenics is considered the acquirer in the transaction for accounting and financial reporting purposes.

 

10
 

 

In connection with the acquisition, ExchangeCo acquired all of the outstanding common shares of CardioGenics (the “CardioGenics Common Shares”), excluding 173,869 CardioGenics Common Shares in the aggregate owned by two (2) minority stockholders of CardioGenics (the “Dissenting Stockholders”), in consideration for the issuance of 422,183,610 shares of our common stock to the CardioGenics stockholders at the closing, as further described below (the “Share Consideration”). In consideration for the surrender of their CardioGenics Common Shares, the CardioGenics stockholders had the option to receive at the closing their pro-rata allocation of the Share Consideration in the form of (a) our common shares or (b) “Exchangeable Shares“ of ExchangeCo, which are exchangeable into our common shares in accordance with the terms of a Voting and Exchange Trust Agreement dated July 6, 2009 among JAG Media, ExchangeCo, and WeirFoulds LLP, as trustee and the rights and preferences of the Exchangeable Shares. Those CardioGenics stockholders who elected to receive directly our common shares were issued, in the aggregate, 145,528,195 common shares at the closing and those CardioGenics stockholders who elected to receive Exchangeable Shares were issued 16 Exchangeable Shares at the closing, which are exchangeable at any time into 276,655,415 of our common shares, in the aggregate. The Share Consideration issued at the closing provided the CardioGenics stockholders with direct and indirect ownership of approximately 85% of our outstanding common stock, on a fully diluted basis.

 

Immediately prior to the closing, all CardioGenics debenture holders converted their debentures into CardioGenics Common Shares in accordance with the terms of their respective debentures, as required by the terms of the Share Purchase Agreement. Accordingly, such former debenture holders became CardioGenics stockholders for purposes of the acquisition and received their pro-rata allotment of the Share Consideration in the form of JAG Common Shares and/or Exchangeable Shares at the closing in consideration for the surrender of the CardioGenics Common Shares they received upon conversion of their debentures.

 

Also prior to the closing, CardioGenics closed on an equity investment round of financing totaling $2,715,000. These equity investors in CardioGenics became CardioGenics stockholders for purposes of the acquisition and received their pro-rata allotment of the Share Consideration in the form of our common shares.

 

All of our common shares received by CardioGenics stockholders in exchange for their CardioGenics Common Shares may not be registered for resale and, therefore, shall remain subject to the rights and restrictions of Rule 144. All Exchangeable Shares received by CardioGenics stockholders in exchange for their CardioGenics Common Shares (and any of our common shares into which such Exchangeable Shares may be exchanged) also may not be registered for resale prior to six (6) months following the closing and, therefore shall remain subject to the rights and restrictions of Rule 144 prior to any such registration.

 

Also at the closing, all holders of CardioGenics warrants entitling the holders to purchase CardioGenics Common Shares at various prices exchanged their CardioGenics warrants for warrants to purchase, in the aggregate, 36,148,896 of our common shares at exercise prices of $0.047 per share, in accordance with the terms of the Share Purchase Agreement and the respective warrants. The terms of these newly issued warrants did not include any registration rights for the warrant holders. CardioGenics had no options to acquire CardioGenics Common Shares outstanding as of the closing.

 

At the closing, our then current directors resigned as directors of JAG Media and its subsidiaries after appointing their successors and our then current officers also resigned as officers and executives of JAG Media and its subsidiaries. After their resignation and the closing, our former directors entered into consulting agreements with the Company pursuant to which they are rendering various services to assist us in connection with certain transition matters. Each consulting agreement is for a term of 18 months, with each party receiving 500,000 shares of the Company’s common stock, issued pursuant to our 1999 Long-Term Incentive Plan, as compensation for their services under the consulting agreements.

 

Following the closing, a majority of our stockholders approved, by written consent, an amendment to our articles of incorporation, which provided for (a) a change in our corporate name from “JAG Media Holdings, Inc.“ to “CardioGenics Holdings Inc.” and (b) an increase in the number of our authorized JAG Common Shares from 500,000,000 to 650,000,000.

 

Financing Arrangements

 

Equity Line of Credit with YA Global

 

In connection with the CardioGenics Acquisition, on March 12, 2009 we entered into a Standby Equity Distribution Agreement with YA Global Master SPV Ltd. (“YA Ltd ”) (the “ SEDA ”) pursuant to which YA Ltd agreed to purchase up to $5,000,000 of our common stock (the “ Commitment Amount ”) over the course of the thirty-six (36) months following the date the registration statement for the shares to be issued pursuant to the SEDA is first declared effective (the “ Commitment Period ”). We will have the right, but not the obligation, to sell common stock to YA Ltd during the Commitment Period. Concurrent with the execution of the SEDA, we also entered into a Registration Rights Agreement with YA Ltd pursuant to which we agreed to register the shares of our common stock to be issued in connection with the SEDA. Such registration was never filed and, accordingly, the SEDA never became effective. Effective March 19, 2010, the Company and YA Ltd. terminated these agreements by mutual consent.

 

11
 

 

Increase in Authorized Shares

 

In October 2009 a majority of our stockholders approved, by written consent, an amendment to our articles of incorporation, which provided for, among other matters, an increase in the number of our authorized shares of common stock from 500,000,000 to 650,000,000.

 

Reverse Stock Split

 

As authorized by our Board of Directors, on June 18, 2010, we filed a “Certificate of Change” with the Nevada Secretary of State’s Office, which effected a 1:10 share consolidation of our outstanding and authorized shares of common stock. As a result of this share consolidation our authorized shares of common stock was reduced from 650,000,000 to 65,000,000 and our outstanding shares of common stock as of such date were consolidated in accordance with the 1:10 share consolidation ratio.

 

Facilities

 

See “Item 2.—Properties.”

 

Legal Proceedings

 

See “Item 3.—Legal Proceedings.”

 

Where You Can Find More Information About Us

 

We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC.  You can read and copy any of this information at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 on official business days during the hours of 10:00 a.m. to 3:00 p.m.  You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.  This information is also available from the SEC’s website at http://www.sec.gov.  We will also gladly send any filing to you upon your written request to Dr. Yahia Gawad, our Chief Executive Officer, at 6295 Northam Drive, Unit 8, Mississauga, Ontario L4V 1W8.

 

ITEM 1A.  RISK FACTORS

 

Risks Related to Our CardioGenics Business and Industry

 

The global financial crisis has had, and may continue to have, an impact on our business and financial condition.

 

The ongoing global financial crisis may limit our ability to access the capital markets at a time when we would like, or need, to raise capital, which could have an impact on our ability to react to changing economic and business conditions. Accordingly, if the global financial crisis and current economic downturn continue or worsen, our business, results of operations and financial condition could be materially and adversely affected.

 

The requirements of being a public company may strain our resources and distract our management

 

As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended and the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”). These requirements place a strain on our systems and resources.  The Exchange Act requires that we file annual, quarterly and current reports with respect to our business and financial condition. The Sarbanes-Oxley Act requires that we maintain effective disclosure controls and procedures and internal controls for financial reporting.  Management has identified the following material weaknesses in our internal controls over financial reporting: 1. lack of documented policies and procedures; 2. lack of resources to account for complex and unusual transactions; and, 3. there is no effective segregation of duties, which includes monitoring controls, between the members of management.

 

We are also required to document and test our internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act, which requires annual management assessments of the effectiveness of our internal controls over financial reporting. We may not be able to remediate these weaknesses in time to meet the deadlines imposed by the Sarbanes-Oxley Act. If we fail to achieve and  maintain the adequacy of our internal controls, as such standards are modified,  supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with the Sarbanes-Oxley Act.


12
 

 

In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, significant resources and management oversight will be required. This may divert management’s attention from other business concerns, which could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, we may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge, and we cannot assure you that we will be able to do so in a timely fashion.

 

We have not earned any significant revenues in our CardioGenics business unit since its incorporation and only have a limited operating history in its current business, which raise doubt about our ability to continue as a going concern.

 

Our CardioGenics business unit has a limited operating history in its current business and must be considered in the development stage. It has not generated any significant revenues since its inception and we will, in all likelihood, continue to incur operating expenses without significant revenues until we complete development of our Cardiovascular Tests and commercialize our QLCA and the Cardiovascular Tests. The primary source of funds for our CardioGenics business unit has been the sale of common stock. We cannot assure that we will be able to generate any significant revenues or income. These circumstances make us dependent on additional financial support until profitability is achieved. There is no assurance that we will ever be profitable and we have not yet achieved profitable operations. These factors raise substantial doubt that we will be able to continue as a going concern.

 

We need to raise additional financing to support the research and development of our CardioGenics business but we cannot be sure that we will be able to obtain additional financing on terms favorable to us when needed. If we are unable to obtain additional financing to meet our needs, our operations may be adversely affected or terminated.

 

Our ability to develop new test products for our QLCA is dependent upon our ability to raise significant additional financing when needed. If we are unable to obtain such financing, we will not be able to fully develop and commercialize our platform and technology. Our future capital requirements will depend upon many factors, including:

 

  continued scientific progress in our research and development programs;
  costs and timing of conducting clinical trials and seeking regulatory approvals and patent prosecutions;
  competing technological and market developments;
  our ability to establish additional collaborative relationships; and
  the effect of commercialization activities and facility expansions if and as required.

 

We have limited financial resources and to date, no material cash flow from the operations of our CardioGenics business unit and we are dependent for funds on our ability to sell our common stock, primarily on a private placement basis. There can be no assurance that we will be able to obtain financing on that basis in light of factors such as the market demand for our securities, the state of financial markets generally and other relevant factors. Any sale of our common stock in the future will result in dilution to existing stockholders. Furthermore, there is no assurance that we will not incur debt in the future, that we will have sufficient funds to repay any future indebtedness or that we will not default on our future debts, jeopardizing our business viability. Finally, we may not be able to borrow or raise additional capital in the future to meet our needs or to otherwise provide the capital necessary to continue the development of our technology, which might result in the loss of some or all of your investment in our common stock.

 

We may acquire other businesses, license rights to technologies or products, form alliances, or dispose of or spin-off businesses, which could cause us to incur significant expenses and could negatively affect profitability.

 

 We may pursue acquisitions, technology licensing arrangements, and strategic alliances, or dispose of or spin-off some of our businesses, as part of our business strategy. We may not complete these transactions in a timely manner, on a cost-effective basis, or at all, and may not realize the expected benefits. If we are successful in making an acquisition, the products and technologies that are acquired may not be successful or may require significantly greater resources and investments than originally anticipated. We may not be able to integrate acquisitions successfully into our existing business and could incur or assume significant debt and unknown or contingent liabilities. We could also experience negative effects on our reported results of operations from acquisition or disposition-related charges, amortization of expenses related to intangibles and charges for impairment of long-term assets.

 

13
 

 

The expiration or loss of patent protection and licenses may affect our future revenues and operating income.

 

Much of our business relies on patent and trademark and other intellectual property protection. Although most of the challenges to our intellectual property would likely come from other businesses, governments may also challenge intellectual property protections. To the extent our intellectual property is successfully challenged, invalidated, or circumvented or to the extent it does not allow us to compete effectively, our business will suffer. To the extent that countries do not enforce our intellectual property rights or to the extent that countries require compulsory licensing of our intellectual property, our future revenues and operating income will be reduced. Our principal patents and trademarks are described in greater detail in the sections captioned, "Patents, Trademarks, and Licenses."

 

Competitors' intellectual property may prevent us from selling our products or have a material adverse effect on our future profitability and financial condition.

 

Competitors may claim that one or more of our products infringe upon their intellectual property. Resolving an intellectual property infringement claim can be costly and time consuming and may require us to enter into license agreements. We cannot guarantee that we would be able to obtain license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject us to significant damages or an injunction preventing the manufacture, sale or use of our affected products. Any of these events could have a material adverse effect on our profitability and financial condition.

 

We may not be able to adequately protect our intellectual property

 

We believe the patents, trade secrets and other intellectual property we use are important to our business, and any unauthorized use of such intellectual property by third parties may adversely affect our business and reputation. We rely on the intellectual property laws and contractual arrangements with our employees, business partners and others to protect such intellectual property rights. Filing, prosecuting, defending and enforcing patents on all of our technologies and products throughout the world would be prohibitively expensive. Competitors may, without our authorization, use our intellectual property to develop their own competing technologies and products in jurisdictions where we have not obtained patent protection. These technologies and products may not be covered by any of our patent claims or other intellectual property rights. Furthermore, the validity, enforceability and scope of protection of intellectual property in some countries where we may conduct business is uncertain and still evolving, and these laws may not protect intellectual property rights to the same extent as the laws of the United States.

 

Many companies have encountered significant problems in protecting and defending their intellectual property rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to “work” the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Moreover, litigation involving patent or other intellectual property matters in the United States or in foreign countries may be necessary in the future to enforce our intellectual property rights, which could result in substantial costs and diversion of our resources, and have a material adverse effect on our business, financial condition and results of operations.

 

We are subject to numerous governmental regulations and it can be costly to comply with these regulations and to develop compliant products and processes.

 

Our products are subject to regulation by the U.S. Food and Drug Administration (“FDA”), and numerous international, federal, and state authorities. The process of obtaining regulatory approvals to market a medical device can be costly and time-consuming, and approvals might not be granted for future products, or additional uses of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain approvals for, future products, or additional uses of existing products, could result in delayed realization of product revenues, reduction in revenues, and in substantial additional costs. In particular, in the United States our products are regulated under the 1976 Medical Device Amendments to the Food, Drug and Cosmetic Act, which is administered by the FDA. We believe that the FDA will classify our products as “Class II” devices, thus requiring us to submit to the FDA a pre-market notification form or 510(k). The FDA uses the 510(k) to substantiate product claims that are made by medical device manufacturers prior to marketing. In our 510(k) notification, we must, among other things, establish that the product we plan to market is “substantially equivalent” to (1) a product that was on the market prior to the adoption of the 1976 Medical Device Amendment or (2) a product that the FDA has previously cleared.

 

14
 

 

The FDA review process of a 510(k) notification can last anywhere from three to six months, and the FDA must issue a written order finding “substantial equivalence” before a company can market a medical device. We are currently developing a group of cardiovascular tests that we will have to clear with the FDA through the 510(k) notification procedures. These test products are crucial for our success and if we do not receive 510(k) clearance for a particular product, we will not be able to market these products in the United States, which will have a material adverse effect on our revenues, profitability and financial condition.

 

In addition, no assurance can be given that we will remain in compliance with applicable FDA and other regulatory requirements once clearance or approval has been obtained for a product. We must incur expense and spend time and effort to ensure compliance with these complex regulations. Possible regulatory actions could include warning letters, fines, damages, injunctions, civil penalties, recalls, seizures of our products and criminal prosecution. These actions could result in, among other things: substantial modifications to our business practices and operations; refunds, recalls, or seizures of our products; a total or partial shutdown of production while we or our suppliers remedy the alleged violation; the inability to obtain future pre-market clearances or approvals; and, withdrawals or suspensions of current products from the market. Any of these events could disrupt our business and have a material adverse effect on our revenues, profitability and financial condition.

 

Changes in third-party payor reimbursement regulations can negatively affect our business.

 

By regulating the maximum amount of reimbursement they will provide for blood testing services, third-party payors, such as HMOs, pay-per-service insurance plans, Medicare and Medicaid, can indirectly affect the pricing or the relative attractiveness of our diagnostic products. For example, the Centers for Medicare and Medicaid Services set the level of reimbursement of fees for blood testing services for Medicare beneficiaries. If third-party payors decrease the reimbursement amounts for blood testing services, it may decrease the amount that physicians and hospitals are able to charge patients for such services. Consequently, we would either need to charge less for our products or incur a reduction in our profit margins. If the government and third-party payors do not provide for adequate coverage and reimbursement levels to allow health care providers to use our products, the demand for our products will decrease.

 

Laws and regulations affecting government benefit programs could impose new obligations on us, require us to change our business practices, and restrict our operations in the future.

 

Our industry is also subject to various federal, state, and international laws and regulations pertaining to government benefit program reimbursement, price reporting and regulation, and health care fraud and abuse, including anti-kickback and false claims laws, the Medicaid Rebate Statute, the Veterans Health Care Act, and individual state laws relating to pricing and sales and marketing practices. Violations of these laws may be punishable by criminal and/or civil sanctions, including, in some instances, substantial fines, imprisonment, and exclusion from participation in federal and state health care programs, including Medicare, Medicaid, and Veterans Administration health programs. These laws and regulations are broad in scope and they are subject to evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our sales or marketing practices. In addition, violations of these laws, or allegations of such violations, could disrupt our business and result in a material adverse effect on our revenues, profitability, and financial condition.

 

Our research and development efforts may not succeed in developing commercially successful products and technologies, which may cause our revenue and profitability to decline.

 

To remain competitive, we must continue to launch new products and technologies. To accomplish this, we must commit substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. We must make ongoing substantial expenditures without any assurance that its efforts will be commercially successful. Failure can occur at any point in the process, including after significant funds have been invested.

 

Promising new product candidates may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others. Even if we successfully develop new products or enhancements or new generations of our existing products, they may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors' innovations. Innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or whether any of our products under development will be launched or whether any products will be commercially successful. Failure to launch successful new products or new uses for existing products may cause our products to become obsolete, causing our revenues and operating results to suffer.

 

15
 

 

New products and technological advances by our competitors may negatively affect our results of operations.

 

Our products face intense competition from our competitors' products. Competitors' products may be safer, more effective, more effectively marketed or sold, or have lower prices or superior performance features than our products. We cannot predict with certainty the timing or impact of the introduction of competitors' products.

 

We depend on key members of our management and scientific staff and, if we fail to retain and recruit qualified individuals, our ability to execute our business strategy and generate sales would be harmed.

 

We are highly dependent on the principal members of our management and scientific staff. The loss of any of these key personnel, including in particular Dr. Yahia Gawad, our Chief Executive Officer, might impede the achievement of our business objectives. We may not be able to continue to attract and retain skilled and experienced scientific, marketing and manufacturing personnel on acceptable terms in the future because numerous medical products and other high technology companies compete for the services of these qualified individuals. We currently do not maintain key man life insurance on any of our employees.

 

The manufacture of many of our products is a highly exacting and complex process, and if we or one of our suppliers encounter problems manufacturing products, our business could suffer.

 

The manufacture of many of our products is a highly exacting and complex process, due in part to strict regulatory requirements. Problems may arise during manufacturing for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials, natural disasters, and environmental factors. In addition, we may use single suppliers for certain products and materials. If problems arise during the production of a batch of product, that batch of product may have to be discarded. This could, among other things, lead to increased costs, lost revenue, damage to customer relations, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred. To the extent we or one of our suppliers experience significant manufacturing problems, this could have a material adverse effect on our revenues and profitability.

 

Significant safety issues could arise for our products, which could have a material adverse effect on our revenues and financial condition.

 

All medical devices receive regulatory approval based on data obtained in controlled testing environments of limited duration. Following regulatory approval, these products will be used over longer periods of time with many patients. If new safety issues arise, we may be required to change the conditions of use for a product. For example, we may be required to provide additional warnings on a product's label or narrow its approved use, either of which could reduce the product's market acceptance. If serious safety issues with one of our products arise, sales of the product could be halted by us or by regulatory authorities. Safety issues affecting suppliers' or competitors' products also may reduce the market acceptance of our products.

 

In addition, in the ordinary course of business, we may be the subject of product liability claims and lawsuits alleging that our products or the products of other companies that we promote, or may be incorporated in our products, have resulted or could result in an unsafe condition for or injury to patients. Product liability claims and lawsuits and safety alerts or product recalls, regardless of their ultimate outcome, may have a material adverse effect on our business, reputation and financial condition, as well as on our ability to attract and retain customers. Product liability losses are self-insured.

 

The international nature of our business subjects us to additional business risks that may cause our revenue and profitability to decline.

 

Since we intend to market our products internationally, our business will be subject to risks associated with doing business internationally. The risks associated with any such operations outside the United States include:

 

changes in foreign medical reimbursement policies and programs;
multiple foreign regulatory requirements that are subject to change and that could restrict our ability to manufacture, market, and sell our products;
16
 
differing local product preferences and product requirements;
trade protection measures and import or export licensing requirements;
difficulty in establishing, staffing, and managing foreign operations;
differing labor regulations;
potentially negative consequences from changes in or interpretations of tax laws;
political and economic instability;
inflation, recession and fluctuations in foreign currency exchange and interest rates; and,
compulsory licensing or diminished protection of intellectual property.

 

These risks may, individually or in the aggregate, have a material adverse effect on our revenues and profitability.

 

Other factors can have a material adverse effect on our future profitability and financial condition.

 

        Many other factors can affect our profitability and financial condition, including:

 

Changes in or interpretations of laws and regulations including changes in accounting standards, taxation requirements and environmental laws in domestic or foreign jurisdictions.

 

Changes in the rate of inflation (including the cost of raw materials, commodities, and supplies), interest rates and the performance of investments held by us.

 

Changes in the creditworthiness of counterparties that transact business with or provide services to our distributors or us.

 

Changes in business, economic, and political conditions, including: war, political instability, terrorist attacks in the U.S. and other parts of the world, the threat of future terrorist activity in the U.S. and other parts of the world and related military action; natural disasters; the cost and availability of insurance due to any of the foregoing events; labor disputes, strikes, slow-downs, or other forms of labor or union activity; and, pressure from third-party interest groups.

 

Changes in our business units and investments and changes in the relative and absolute contribution of each to earnings and cash flow resulting from evolving business strategies, changing product mix, changes in tax rates both in the U.S. and abroad and opportunities existing now or in the future.

 

Changes in the buying patterns of a major distributor, retailer, or wholesale customer resulting from buyer purchasing decisions, pricing, seasonality, or other factors, or other problems with licensors, suppliers, distributors, and business partners.

 

Difficulties related to our information technology systems, any of which could adversely affect business operations, including any significant breakdown, invasion, destruction, or interruption of these systems.

 

Changes in credit markets impacting our ability to obtain financing for our business operations.

 

Legal difficulties, any of which could preclude or delay commercialization of products or adversely affect profitability, including claims asserting statutory or regulatory violations, adverse litigation decisions, and issues regarding compliance with any governmental consent decree.

 

Risks Related to Our Capital Structure

 

Our shareholders may experience significant dilution from the exercise of warrants to purchase shares of our common stock.

 

As a result of our acquisition of CardioGenics, former CardioGenics warrant holders exchanged their warrants to purchase CardioGenics Common Shares for warrants to purchase our Common Shares. Currently, the warrants held by such former CardioGenics warrant holders entitle them to purchase up to 3,276,879 of our Common Shares at prices of $0.47 per share.

 

Accordingly, you may experience substantial dilution upon exercise of these warrants. In addition, you may experience substantial dilution if the price of our Common Shares increases to a level greater than the exercise price of these warrants.

 

17
 

 

Future Issuance of Our Common Stock Could Dilute Current Stockholder or Adversely Affect the Market.

 

Future issuances of our common stock could be at values substantially below the price paid by the current holders of our common stock. In addition, common stock could be issued to fend off unwanted tender offers or hostile takeovers without further stockholder approval. Sales of substantial amounts of our common stock in the public market, or even just the prospect of such sales, could depress the prevailing market price of our common stock and our ability to raise equity capital in the future.

 

The market for our common stock is limited.

 

Our common stock is traded on the OTC Bulletin Board. Trading activity in our stock has fluctuated and at times been limited. We cannot guarantee that a consistently active trading market for our stock will continue, especially while we remain on the OTC Bulletin Board.

 

Because our common stock currently trades below $5.00 per share and is quoted on the OTCBB, our common stock is considered by the SEC to be a “penny stock,” which adversely affects our liquidity.

 

Our common stock does not currently qualify for listing on any national securities exchange, and we do not anticipate that it will qualify for such a listing in the short-term future. If our common stock continues to be quoted on the OTC Bulletin Board or is traded on the Pink Sheets or other over-the-counter markets, and if the trading price of our common stock remains less than $5.00 per share, our common stock is considered a “penny stock,” and trading in our common stock is subject to the requirements of Rule 15g-9 under the Exchange Act. Under this rule, brokers or dealers who recommend low-priced securities to persons other than established customers and accredited investors must satisfy special sales practice requirements. The broker or dealer must make an individualized written suitability determination for the purchaser and receive the purchaser’s written consent prior to the transaction. SEC regulations also require additional disclosure in connection with any trades involving a penny stock, including the delivery, prior to any penny stock transaction, of a disclosure schedule explaining the penny stock market and its associated risks. These requirements could severely limit the liquidity of such securities in the secondary market because few brokers or dealers are likely to undertake these compliance activities. In addition to the applicability of the penny stock rules, another risk associated with trading in penny stocks may be large price fluctuations.

 

Our amended charter contains provisions that may discourage an unaffiliated party to take us over.

 

Without further stockholder action, our Board of Directors could authorize the issuance of additional shares of our common stock as well as preferred stock with special voting rights by class or with more than one vote per share, to a “white knight” in order to deter a potential buyer.  This might have the effect of preventing or discouraging an attempt by a party unable to obtain the approval of our Board of Directors to take over or otherwise gain control of us.

 

Terms of subsequent financings may adversely impact your investment.

 

We may have to raise equity, debt or preferred stock financing in the future. Your rights and the value of your investment in our Common Shares could be reduced. For example, if we issue secured debt securities, the holders of the debt would have a claim against our assets that would be prior to the rights of stockholders until the debt is paid. Interest on these debt securities would increase costs and negatively impact operating results.

 

Preferred stock could be issued in series from time to time with such designations, rights, preferences, and limitations as needed to raise capital. The terms of preferred stock could be more advantageous to those investors than to the holders of our Common Shares.

 

Our articles of incorporation do not provide stockholders the pre-emptive right to buy shares from the company. As a result, you will not have the automatic ability to avoid dilution in your percentage ownership of the company.

 

18
 

 

Control of our stock is now held by the former CardioGenics shareholders.

 

The prior shareholders of CardioGenics, as of the closing of the CardioGenics Acquisition, owned, directly or indirectly, approximately 85% of our outstanding common stock. While their percentage would decline if and to the extent new shares of our common stock are issued, you should expect these persons to exert continuing influence over all matters requiring shareholder approval, including the election of directors. You may have little to no practical control over such matters.

 

It is not likely that we will pay dividends on the common stock or any other class of stock

 

We intend to retain any future earnings for the operation and expansion of our business. We do not anticipate paying cash dividends on our common stock, or any other class of stock, in the foreseeable future. Stockholders should look solely to appreciation in the market price of our Common Shares to obtain a return on investment.

 

Our stockholders ownership of our common stock may be in doubt due to possible naked short selling of our common stock.

 

We believe, but cannot confirm, that speculators may have engaged in a practice commonly known as a “naked short” sale of our common stock, which means that certain brokers may be permitting their short selling customers to sell shares of our common stock that their customers do not own and may have failed to borrow and therefore deliver the shares sold to the purchaser of the shares. We have from time to time been included by NASDAQ on the Regulation SHO Threshold Security List, which is indicative of a significant amount of naked shorting in the stock. Because naked shorting may result in an artificial depression of our stock price, our stockholders could lose all or part of their investment in our common stock. As a result of this naked short selling, there may be a substantial number of purchasers who believe they are our stockholders, but who in fact would not be stockholders since their brokers may never have received any shares of our common stock for their account. In addition, investors who believe they are our stockholders may not have received a stock dividend to which they are entitled or may have been deprived of the right to vote some or all of their shares.

 

ITEM 1B.  UNRESOLVED STAFF COMMENTS

 

Not Applicable.

 

ITEM 2.  PROPERTIES

 

Our executive and administrative headquarters are currently located at 6295 Northam Drive, Units 6 through 9, Mississauga, Ontario L4V 1W8 Canada. We rent this space at a cost of CDN$6,432 per month.

 

The servers for our websites are housed at separate locations as described above.  See “Item 1.—Business—Website Technical Information.”  We believe that our facilities are adequate for our current needs and that, if our lease is not renewed on commercially reasonable terms, we will be able to locate suitable new office space and obtain a suitable replacement for our executive and administrative headquarters.

 

ITEM 3.  LEGAL PROCEEDINGS

 

On April 22, 2009, CardioGenics was served with a statement of claim in the Province of Ontario, Canada, from a prior contractor claiming compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in CardioGenics, with an aggregate claim of $514,000.  The Company considers all the claims to be without any merit, has already delivered a statement of defence and intends to vigorously defend the action.  If the matter eventually proceeds to trial, the Company does not expect to be found liable on any ground or for any cause of action.

 

On January 14, 2010, Flow Capital Advisors Inc. (“Flow Capital”) filed a lawsuit against JAG Media Holdings Inc. in the Circuit Court of the 17th Judicial Circuit In and For Broward County Florida (Case No. 10001713) (the “Flow Capital State Action”).  Pursuant to this lawsuit, Flow Capital alleges that JAG Media Holdings breached a Non-Circumvention Agreement it had entered into with Flow Capital, dated January 1, 2004. 

 

19
 

 

On January 15, 2010 Flow Capital filed a lawsuit against CardioGenics Inc., and another defendant in the United States District Court for the Southern District of Florida, Fort Lauderdale Division (Case No. 10-CV-60066-Martinez-Brown) (the “Flow Capital Federal Action”). This lawsuit alleges that CardioGenics (i) breached a Finder’s Fee Agreement in connection with the CardioGenics Acquisition; and (ii) breached a non-circumvention agreement. Flow Capital is claiming that it is entitled to the finder’s fee equal to eight percent (8%) of the JAG Media Holdings shares received by CardioGenics, or the equivalent monetary value of the stock. Plaintiff subsequently amended its complaint to add related tort claims.

 

Pursuant to applicable federal court rules, the parties to the Flow Capital Federal Action participated in a court mandated mediation session on August 17, 2011 where the parties attempted to settle their disputes. At the mediation, the parties agreed to a settlement of all claims as described below, subject to the approval of the Board of Directors of CardioGenics Holdings Inc., which approval was subsequently obtained. Pursuant to the settlement agreement, Flow Capital agreed to dismiss, with prejudice, the Flow Capital Federal Action and the Flow Capital State Action and CardioGenics agreed to issue Flow Capital 1,000,000 shares of restricted CardioGenics Holdings common stock and warrants to purchase restricted CardioGenics Holdings common stock as follows:

 

Type of Warrant   Number of Shares   Exercise Price   Vesting Date   Term
Cash Exercise Only   250,000   0.30/share   immediate   5 years
Cash Exercise Only   250,000   0.50/share   immediate   5 years
Cash Exercise Only   500,000   0.75/share   immediate   5 years
Cash Exercise Only   500,000   1.00/share   immediate   5 years
Cash or Cashless Exercise   500,000   0.75/share   August 1, 2012   5 years

 

The restricted shares of common stock and the warrants are subject to the rights and restrictions of Rule 144A and do not have any registration rights. As part of the settlement, the parties also exchanged mutual general releases and CardioGenics Holdings agreed to pay Flow Capital, in three monthly installments, $100,000 for Flow Capital’s legal fees.

 

On August 23, 2011, the Company’s Board of Directors approved the settlement.  As a result, the Company recorded a charge to the Condensed Statement of Operations at July 31, 2011 of $1,753,800 for Cost of Settlement of Lawsuit.

 

On October 26, 2010 Karver International Inc. filed a lawsuit in the 11th Judicial Circuit in and for Miami-Dade County, Florida against CardioGenics Holdings Inc. and several other defendants including affiliates, officers and directors of CardioGenics Holdings, Inc.  The Plaintiff generally alleges that the named defendants made certain alleged misrepresentations in connection with the purchase of shares of CardioGenics Holdings Inc.  On December 20, 2010 CardioGenics Holdings Inc. and other defendants filed a motion to dismiss on the basis that the court lacks personal jurisdiction over most defendants, that an enforceable forum selection clause requires that the action be litigated in Ontario, Canada that the doctrine of forum non conveniens requires dismissal in favor of the Ontario forum, and that the complaint suffers from numerous other technical deficiencies warranting dismissal (e.g., failure to attach documents to the Complaint, failure to plead fraud with particularity, etc.). In addition, prior to the motion being heard, Karver’s attorney filed a motion to withdraw as counsel for Karver. The court granted Karver’s attorney’s motion to withdraw and Karver had until approximately April 26, 2011 to engage new counsel. On April 20, 2011, having not engaged new counsel as of that date, Karver filed with the court a Notice of Voluntary Dismissal Without Prejudice, which dismisses the lawsuit against the named defendants without prejudice to Karver’s rights to recommence the action.

 

While it is not feasible to predict the outcome of the above proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on the Company's financial position, cash flows or results of operations.

 

ITEM 4.  (REMOVED AND RESERVED)

20
 

 

PART II

 

ITEM 5.  MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF SECURITIES

 

For the period covered below, our common stock (other than our class B common stock) is traded on the OTC Bulletin Board under the symbol CGNH. In October 2009, our symbol was changed from JAGH to CGNH as a result of the CardioGenics Acquisition. The following table based on Bloomberg L.P. reflects quarterly high and low bid prices of our common stock from October 31, 2010 through October 31, 2011.  Such prices are inter-dealer quotations without retail mark-ups, mark-downs or commissions, and may not represent actual transactions.

 

Fiscal Year Ending October 31, 2011            
Quarter Ended   High $     Low $  
October 31, 2011     0.65       0.30  
July 31, 2011     0.80       0.55  
April 30, 2011     1.08       0.60  
January 31, 2011     1.39       0.87  
Fiscal Year Ending October 31, 2010                
Quarter Ended   High $     Low $  
October 31, 2010     2.27       1.47  
July 31, 2010     2.13       1.19  
April 30, 2010     2.93       0.697  
January 31, 2010     0.93       0.52  

 

On January 11, 2012, the closing bid price for our common stock was $0.30.  A public trading market for our Series 2 and Series 3 Class B common stock, which were redeemed on April 4, 2011, never developed.

 

As of January 11, 2012, there were 30,896,649 shares of our common stock outstanding. There was also outstanding 1 share of Series 1 Preferred Voting Stock, par value $0.0001, representing 14 Exchangeable Shares, which are exchangeable into 24,388,908 shares of our common stock.

 

In addition, there are 1,318 additional stockholders who did not turn in their shares of prior classes of our common stock in connection with our recapitalizations in 2002 and 2004.  These shares are exchangeable into shares of our common stock. As of January 11, 2012, 17,360 Series 1 Class B common shares, 107,365 Class A common shares and 12,366 original JagNotes.com Inc. common shares remained unconverted.

 

Dividend Policy

 

We have never paid any cash dividends on our common stock and anticipate that, for the foreseeable future, no cash dividends will be paid on our common stock.

 

Equity Compensation Plans Information

 

See the information provided under “Item 12.—Security Ownership of Certain Beneficial Owners and Related Stockholder Matters—Equity Compensation Plan Information.”

 

Recent Sales of Unregistered Securities

 

On May 25, 2006 we issued 1,250,000 shares of our common stock to YA Global as repayment for $250,000 of the outstanding principal amount of the Promissory Note and a $1,900,000 10% secured convertible debenture with a maturity of three years in consideration of the remaining $1,750,000 of the outstanding principal amount of the Promissory Note and $150,000 in accrued and unpaid interest.  This issuance was exempt from registration under the Securities Act, pursuant to Section 3(a)(9) thereof.

 

In May of 2006, we issued two secured convertible debentures to YA Global in an aggregate principal amount of $1,250,000, as follows: (i) a $1,250,000 10% secured convertible debenture and (ii) a $1,000,000 10% secured convertible debenture, each with a maturity of three years.  This issuance was exempt from registration under the Securities Act, pursuant to Section 4 (2) thereof, as YA Global is an accredited investor.

 

21
 

 

Pursuant to the terms of the secured convertible debentures, YA Global has converted the entire principal and accrued interest on the debentures into an aggregate of 14,651,265 shares of common stock, as set forth below:

 

Date

 

Principal Amount Converted

   

Number of Shares

 
June 28, 2006   $ 25,000       125,313  
July 21, 2006   $ 50,000       279,642  
August 3, 2006   $ 50,000       279,642  
August 15, 2006   $ 50,000       289,855  
September 14, 2006   $ 50,000       556,793  
September 18, 2006   $ 50,000       556,793  
November 20, 2006   $ 150,000       1,246,883  
November 30, 2006   $ 105,000       872,818  
January 5, 2007   $ 100,000       629,327  
August 23, 2007   $ 500,000       1,250,000  
August 28, 2007   $ 420,000       1,050,000  
September 25, 2007   $ 550,000       1,375,000  
September 28, 2007   $ 130,000       325,000  
November 14, 2007   $ 300,000       750,000  
December 17, 2007   $ 1,000,000       2,500,000  
January 24, 2008   $ 295,000       737,500  
January 31, 2008   $ 860,679       2,151,699  

 

On May 25, 2006, as partial consideration for YA Global’s purchase of the secured convertible debentures, we issued five warrants to purchase an aggregate of 12,000,000 shares of our common stock, as follows.  For a description of such warrants, see “Item 1.—Business—Financing Arrangements—Warrants.”  This issuance was exempt from registration under the Securities Act, pursuant to Section 4(2) thereof, as YA Global is an accredited investor.

 

Pursuant to the terms of the warrants, as amended, YA Global has exercised all of the shares under the warrants as follows:

 

Warrant No.   Exercise Date   # of Shares Exercised     Exercise Price     Gross Proceeds  
CCP-1   January 31, 2008     700,000     $ 0.40     $ 280,000  
    May 16, 2008     1,300,000     $ 0.40     $ 520,000  
CCP-2   April 30, 2009     2,000,000     $ 0.05     $ 100,000  
CCP-3   March 12, 2009     2,000,000     $ 0.07     $ 140,000  
CCP-4   September 30, 2008     1,750,000     $ 0.20     $ 350,000  
    May 29, 2009     625,000 *   $ 0.20     $ 0.00  
CCP-5   June 1, 2009     2,000,000     $ 0.40     $ 800,000  
    July 28, 2009     750,000     $ 0.18     $ 135,000  
    August 4, 2009     250,000     $ 0.18     $ 45,000  
          11,375,000             $ 2,370,000  

       *This portion of warrant No CCP-4 was exercised on a “cashless basis“ resulting in a reduction of 625,000 warrant shares under this warrant

 

The Company claims an exemption from the registration requirements of the Securities Act of 1933, as amended, for the issuance of shares to as provided above pursuant to Section 4(2) of the Act and/or Rule 506 of Regulation D promulgated thereunder since, among other things, the transaction does not involve a public offering, the purchaser is an “accredited investor” and/or qualified institutional buyers, the purchaser has access to information about the Company and its purchase, the purchaser will take the securities for investment and not resale, and the Company is taking appropriate measures to restrict the transfer of the securities.

 

Purchases of Equity Securities

 

There were no repurchases made for any class or series of securities in a month within the fourth quarter of the fiscal year ended October 31, 2011.

 

22
 

 

ITEM 6.  SELECTED FINANCIAL DATA

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide information under this item.

 

ITEM 7.  MANAGEMENT’S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

 

This annual report contains forward-looking statements relating to future events or our future financial performance.  In some cases you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “estimates,” “predicts,” “potential,” “continue,” “strategy,” “believes,” “anticipates,” “plans,” “expects,” “intends” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors which may cause our or our industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements.

 

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity or performance.  You should not place reliance on these statements, which speak only as of the date that they were made.  These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future.  Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward –looking statements to conform these statements to actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

 

In this annual report unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares of our capital stock.

 

The management’s discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

The financial statements contained herein include the results CardioGenics, Inc. and its subsidiaries and CardioGenics  Holdings, Inc. and its subsidiaries (“CardioGenics Holdings, Inc.”) (the latter from July 31, 2009, date of acquisition) which are collectively referred to as the “Company.”

 

CardioGenics Holdings, Inc. was until February 11, 2010 a provider of Internet-based equities research and financial information that offered its subscribers a variety of stock market research, news and analysis, including "JAG Notes", CardioGenics Holdings, Inc.'s flagship early morning consolidated research product.

 

On July 31, 2009, JAG Media Holdings, Inc. completed a reverse acquisition of privately held CardioGenics Inc. (“CardioGenics”), an Ontario, Canada Corporation. The acquisition was effected pursuant to a Share Purchase Agreement dated May 22, 2009 by and among JAG Media Holdings, Inc., CardioGenics Inc. and CardioGenics ExchangeCo Inc., the Company’s wholly owned subsidiary (“ExchangeCo”). In accordance with the terms of the Share Purchase Agreement, 99% of the holders of common shares of CardioGenics Inc. (two (2) minority shareholders of CardioGenics holding in aggregate 17,387 common shares of CardioGenics Inc. did not participate) surrendered their CardioGenics Common Shares to ExchangeCo. ExchangeCo caused JAG Media Holdings, Inc. to issue to the CardioGenics shareholders 42,218,361 shares of the Company’s common stock, par value $0.00001 per share (the “Share Consideration”). The Share Consideration provides the former CardioGenics shareholders with direct and/or indirect ownership of approximately 85% of JAG Media Holdings, Inc.’s outstanding common stock (on a fully diluted basis) as of July 31, 2009.

 

On October 27, 2009 the name of the Company was changed from Jag Media Holdings, Inc. to CardioGenics Holdings, Inc.

 

CardioGenics develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. CardioGenics has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under  development by CardioGenics, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, CardioGenics has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. CardioGenics’ principal offices are located in Mississauga, Ontario, Canada.

 

With the acquisition of CardioGenics, the Company’s business is now refocused on developing technologies and products for the point-of-care In Vitro Diagnostics market.

23
 

 

On February 11, 2010, the Company entered into an LLC Membership Interest Purchase Agreement with Rothcove Partners LLS (“Rothcove”) pursuant to which the Company sold its interest in the Internet-based equities research and financial information business to Rothcove.

 

On April 23, 2010, the Company’s Board of Directors approved a reverse stock split of its issued and outstanding common shares.  The total authorized shares of common stock was at the same time reduced to 65,000,000.  The Board of Directors selected a ratio of one-for-ten and the reverse stock split was effective on June 20, 2010.  Trading of the Company’s common stock on the Over-The-Counter Capital Market on a split adjusted basis began at the open of trading on June 21, 2010.  The reverse stock split affected all shares of the Company’s common stock, as well as options to purchase the Company’s common stock and other equity incentive awards and warrants that were outstanding immediately prior to the effective date of the reverse stock split.  All references to common shares and per-share data for prior periods have been retroactively restated to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented.

 

Results of Operations for the Years Ended October 31, 2011 and October 31, 2010

 

The following table sets forth the Company’s results of operations for the years ended October 31, 2011 and October 31, 2010:

 

    Years Ended October 31,  
    2011     2010  
    (Restated)        
Revenue   $ 8,876     $  
                 
Operating Expenses:                
Depreciation and amortization of property and equipment     20,399       20,932  
Amortization of patent application costs     5,207       3,023  
Write-off of patent application costs     55,549       105,345  
General and administrative     3,398,960       1,246,887  
Cost of settlement of lawsuit     1,753,800        
Research and product development, net of investment tax credits     426,007       605,658  
Total operating expenses     5,659,922       1,981,845  
                 
Operating loss     (5,651,046 )     (1,981,845 )
                 
Other Expenses:                
Interest expense and bank charges (net)     20,135       30,166  
Loss on foreign exchange transactions     90,737       104,182  
Total other expenses     110,872       134,348  
                 
Loss from Continuing Operations     (5,761,918 )     (2,116,193 )
                 
Discontinued Operations:                
Gain on sale of subsidiary           90,051  
Loss from discontinued operations           (12,355 )
Net Loss   $ (5,761,918 )   $ (2,038,497 )

 

Revenues

 

Cardiogenics commenced selling paramagnetic beads.  Revenues reflect sales of beads in the last quarter of 2011.

 

24
 

 

Operating expenses

 

General and administrative expenses

 

General and administrative expenses consist primarily of compensation to officers, occupancy costs, professional fees, listing costs and other office expenses. The change in general and administrative expenses is attributable primarily to an increase in professional and consulting fees partially offset by a reduction in share compensation rewarded to officers in the current period to nil.

 

Research and product development costs, net of investment tax credits

 

Research and development expenses consist primarily of salaries and wages paid to officers and employees engaged in those activities and supplies consumed therefor. The change in research and development expenses is attributable primarily to an increase in staff engaged in R&D in 2011, offset by a Canadian refundable tax credit not obtained in the prior year.

 

Cost of settlement of lawsuit

 

On August 17, 2011, the Company and Flow Capital Advisors Inc. participated in a court mandated mediation session wherein the parties agreed to a settlement of all claims.  On August 23, 2011, the Company’s Board of Directors approved the settlement.  As a result, the consolidated statements of operations for the year ended October 31, 2011 reflects a charge of $1,753,800 for the cost of settlement of lawsuit.

 

Other expenses

 

Interest expense and bank charges, net

 

The decrease in interest expense of approximately $10,000 arises from the fact that cash was obtained from the issuance of common shares in the last quarter of 2010 and the first quarter of 2011.

 

Loss from discontinued operations and gain on sale of subsidiary

 

On February 11, 2010, the Company sold its JAG Media division, realizing a gain of approximately $90,000.  The Company has treated the operating results of that division in these consolidated financial statements as loss from discontinued operations.

 

Loss on foreign exchange transactions

 

The Company conducts the majority of its transactions in Canadian dollars. The foreign exchange loss (2011-$90,737, 2010-$104,182) results from currency movements on transactions settled during the year.

 

Liquidity and Capital Resources

 

For the year ended October 31, 2011 the Company incurred a net loss of approximately $5,762,000 (2010-$2,038,000) and a cash flow deficiency from operating activities of approximately cash flow $1,521,000 (2010-$2,163,000). The Company has not yet established an ongoing source of revenues sufficient to cover our operating costs and allow us to continue as a going concern.  The Company has funded its activities to date almost exclusively from debt and equity financings.  These matters raise substantial doubt about the Company’s ability to continue as a going concern and our independent auditors included an explanatory paragraph to emphasize such doubt in their report on the audit of our financial statements.

 

The Company will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of our products, and to commence sales and marketing efforts.  The Company’s plans include financing activities such as private placements of its common stock and issuances of convertible debt instruments.  The Company is also actively pursuing industry collaboration activities including product licensing and specific project financing.

 

The Company believes that it will be successful in obtaining the necessary financing to fund its operations, meet revenue projections and manage costs; however, there are no assurances that such additional funding will be achieved and that the Company will succeed in its future operations.

 

Our current annual cash requirement is approximately $1,500,000. The cash balance at the year end was $669,202 meaning that we had sufficient cash reserves to cover greater than 5 months operations, assuming no revenue over the period. We are in fact anticipating revenues during the next fiscal year.

 

25
 

 

Off-Balance Sheet arrangements

 

The Company is not a party to any off balance sheet arrangements.

Seasonality

 

The Company does not believe that its business is materially affected by seasonal trends or inflation. On an ongoing basis, the Company will attempt to minimize any effect of inflation on its operating results by controlling operating costs.

 

Summary of Critical Accounting Policies and Estimates

 

The discussion and analysis of the Company’s financial condition and results of its operations are based upon its consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America for financial statements filed with the SEC.

 

  (a) Convertible Debentures

In accordance with guidance in accounting for convertible securities with beneficial conversion features or contingently adjustable conversion ratios, the Company recognized an embedded beneficial conversion feature present in the convertible debentures. The Company allocated a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital.  The debt discount attributed to the beneficial conversion feature is amortized over the convertible debenture's maturity period as interest expense using the effective yield method.

 

In addition, the Company recognized the value attributable to the warrants to additional paid-in capital and a discount against the convertible debentures. The Company valued the warrants using the Black-Scholes pricing model.  The debt discount attributed to the value of the warrants issued is amortized over the convertible debenture’s maturity period as interest expense using the effective yield method.

 

  (b) Research and Development Costs

Expenditures for research and development are expensed as incurred and include, among other costs, those related to the production of prototype products, including payroll costs. Amounts expected to be received from governments under Scientific Research Tax Credit arrangements are offset against current expenses.  The Company recognizes revenue from restricted grants in the period in which the Company has for refundable tax credits incurred the expenditures in compliance with the specific restrictions.

 

  (c) Income Taxes

The Company utilizes the liability method of accounting for income taxes as set forth in the authoritative guidance. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. As there is no certainty that the Company will generate taxable income in the foreseeable future to utilize tax losses accumulated to date, no provision for ultimate tax reduction has been made in these financial statements.

 

On November 1, 2007, the Company adopted the guidance issued for accounting for uncertainty in income taxes which provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements. Income tax positions must meet a more-likely-than-non recognition threshold at the effective date to be recognized upon the adoption of the guidance and in subsequent periods. The Company recognizes potential accrued interest and penalties related to unrecognized tax benefits within operations as income tax expense. Upon adoption, there were no adjustments required.

 

26
 
  (d) Stock-Based Compensation

The Company follows the authoritative guidance for stock-based compensation which requires that new, modified and unvested share-based payment transactions with employees, such as grants of stock options and restricted stock, be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over their vesting periods. The Company has also considered the related guidance of the Securities and Exchange Commission (“SEC”). The Company estimates the fair value of stock options and shares issued as compensation to employees and directors as of the date of grant using the Black-Scholes pricing model and restricted stock based on the per share value.  The Company also follows the guidance for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants which  provides guidance on transactions in which (1) the fair value of the equity instruments is more reliably measurable than the fair value of the goods or services received and (2) the counterparty receives shares of stock, stock options, or other equity instruments in settlement of the entire transaction or, if the transaction is part cash and part equity instruments, in settlement of the portion of the transaction for which the equity instruments constitute the consideration.  Options issued with a nominal exercise price in exchange for services rendered were measured at the fair value of the underlying services rendered on the date of grant. The expense was recorded to the statement of operations with a corresponding increase in share capital with no additional increase in the number of shares as they were legally not yet exercised.

 

  (e) Foreign Currency Translation

The Company maintains its accounting records for its Canadian operations in Canadian dollars. Transactions in United States dollars (“USD”) are translated into Canadian dollars at rates in effect at the date of the transaction and gains or losses on such transactions are recorded at the time of settlement in the statement of operations.

 

The Company’s reporting currency is the United States Dollar.  Foreign denominated assets and liabilities of the Company are translated into USD at the prevailing exchange rates in effect at the end of the reporting period, the historical rate for stockholders’ equity (deficiency) and a weighted average of exchange rate in effect during the period for expenses, gains and losses.  Adjustments that arise from translation into the reporting currency are recorded in the accumulated other comprehensive income (loss) component of stockholders’ equity (deficiency).

 

  (f) Non-controlling Interest in Consolidated Financial Statements

The Company follows the authoritative guidance for accounting and reporting for minority interests which characterizes non-controlling interests as a component of equity within the consolidated balance sheets.

 

Recent Accounting Pronouncements

 

In May 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2011-04, Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs (“ASU 2011-04”). ASU 2011-04 represents the converged guidance of the FASB and the International Accounting Standards Board on fair value measurement. The guidance clarifies how a principal market is determined, addresses the fair value measurement of instruments with offsetting market or counterparty credit risks, addresses the concept of valuation premise and highest and best use, extends the prohibition on blockage factors to all three levels of the fair value hierarchy and requires additional disclosures. ASU 2011-04 is effective for interim and annual periods beginning after December 15, 2011 and is applied prospectively. The Company will adopt the requirements of ASU 2011-04 in the first quarter of 2012 and anticipates a negligible impact on its financial statements.

 

In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income (“ASU 2011-05”). The issuance of ASU 2011-05 is intended to improve the comparability, consistency and transparency of financial reporting and to increase the prominence of items reported in other comprehensive income. The guidance in ASU 2011-05 supersedes the presentation options in ASC Topic 220 and facilitates convergence of U.S. GAAP and IFRS by eliminating the option to present components of other comprehensive income as part of the statement of changes in equity and requiring that all non-owner changes in equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. ASU 2011-05 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. The Company plans to implement the provisions of ASU 2011-05 by presenting a separate statement of other comprehensive income following the statement of operations beginning in fiscal 2013.

 

In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities. ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (IFRS). The new standards are effective for annual periods beginning January 1, 2013, and interim periods within those annual periods. Retrospective application is required. The Company will implement the provisions of ASU 2011-11 beginning in fiscal 2014.

 

27
 

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide information under this item.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

The consolidated financial statements and supplementary data required in this item are set forth beginning on Page F-1 of this Annual Report on Form 10-K.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

2011

None

 

2010

None

 

ITEM 9A(T). CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management is responsible for establishing and maintaining adequate disclosure controls and procedures as defined in Rule 13a-15(e) and 15(d)-15(e) of the Exchange Act.  Our management conducted an evaluation of the effectiveness of disclosure controls and procedures and concluded that our disclosure controls and procedures was not effective as of October 31, 2011 primarily due to material weaknesses in internal controls over financial reporting (see below).

 

Management’s Report on Internal Controls Over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and preparation of financial statement for external purposes in accordance with U.S. generally accepted accounting principles. A control system, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Because of the inherent limitations in all control systems, internal controls over financial reporting may not prevent or detect misstatements. The design and operation of a control system must also reflect that there are resource constraints and management is necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible controls.

 

Our management concluded that as at October 31, 2011 our internal controls over financial reporting were not effective based on the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organization of the Treadway Commission. Management has identified the following material weaknesses in our internal controls over financial reporting:

 

  · lack of documented policies and procedures;

 

  · lack of resources to account for complex and unusual transactions: and

 

  · there is no effective separation of duties, which includes monitoring controls, between the members of management.

 

Management is currently evaluating what steps can be taken in order to address these material weaknesses.

28
 

 

This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm regarding internal controls over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to the rules of the SEC that permit us to provide only a management’s report.

 

Changes in Internal Controls Over Financial Reporting

 

There were no significant changes (including corrective actions with regard to significant deficiencies or material weaknesses) in our internal controls over financial reporting that occurred during the quarter ended October 31, 2011, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B. OTHER INFORMATION

 

There are no items that required disclosure in a Form 8-K during the fourth quarter of the year covered by this Form 10-K that were not reported by the Company.

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

The following table sets forth the name, age and position of each of the members of our board of directors, executive officers and certain significant employees as of the fiscal year ending October 31, 2010.

 

Board of Directors and Executive Officers

 

Name Age   Position
Yahia Gawad 53   Director & Chief Executive Officer
       
Alexander D.G. Reid 73   Director
       
J. Neil Tabatznik 61   Director/Acting Chairman
       
Linda J. Sterling 50   Director & Secretary
       
James A. Essex 63   Chief Financial Officer

 

There are no family relationships among the directors and executive officers. All directors are elected to hold office until the next annual meeting of stockholders following election and until their successors are duly elected and qualified. Executive officers are appointed by the Board of Directors and serve at the discretion of the Board.

 

We know of no pending proceedings to which any director, member of senior management, or affiliate is either a party adverse to us, or our subsidiary, or has a material interest adverse to us or our subsidiaries.

 

None of our executive officers or directors have been involved in any bankruptcy proceedings within the last five years, been convicted in or has pending any criminal proceedings, been subject to any order, judgment or decree enjoining, barring, suspending or otherwise limiting involvement in any type of business, securities or banking activity or been found to have violated any federal, state or provincial securities commodities law.

 

Yahia Gawad, MB, Ch.B., MD, MSc. (age 53, Director and Chief Executive Officer of CardioGenics since 1997). Dr. Gawad is a Physician/Scientist with primary training in Cardiology, Biochemistry and Immunology.  He received his medical education and post-graduate training at the University of Alexandria and the University of Toronto. Dr. Gawad's academic and commercial experience and expertise include many years of designing and managing cardiovascular disease research and product development.

 

Dr. Gawad was a co-founder of a division of Nanogen (NGEN) (formerly Syn X and Skye Pharmatech) where he held the position of Vice-President, Medical Affairs. Prior to that, he was Director of Clinical Research and Development at Spectral Diagnostics Inc. (now Nanogen).

29
 

 

For the past 16 years, he has been working extensively on cardiac diagnostic test products.  He has prepared, submitted and obtained FDA regulatory approvals for several cardiac test products currently being marketed (including Cardiac Status Troponin I®, Myoglobin® and Myoglobin/CK-MB®, registered trademarks of Spectral Diagnostics Inc.). Through his expertise and contributions to an international committee, a new cardiac test, Troponin I, is now in routine clinical use.

 

In addition, Dr. Gawad has researched, developed and published several other tests. Dr. Gawad has received several awards and scholarships and was a member of both the Clinical Committee of the American Heart Association and the POC division of the American Association for Clinical Chemistry. He has served as a reviewer for the editorial board of the American Journal of Cardiology (1999-2003). Dr. Gawad published extensively and presented his research and clinical findings at national and international symposia.

 

J. Neil Tabatznik (age 61, Director of CardioGenics since 2005, Acting Chairman of CardioGenics since 2009). Mr. Tabatznik is the Chairman, CEO of Arrow Pharmaceuticals Inc. Arrow Pharmaceuticals is part of a global generic drug company established in 2000, and has seen rapid growth from $0 to $700 million in 8 years. The Arrow Group has sales operations in 5 continents and employs more than 1000 people worldwide. Prior to Arrow Pharmaceuticals, Mr. Tabatznik was the Chairman, CEO of Genpharm Inc. (1993-2000), which was acquired by MerckKGaA in 1994 and is now a part of Mylan Inc. the world's third largest generic and specialty pharmaceutical company. He was a Barrister-at-Law in London and was called to the Bar of England and Wales in 1978. He has extensive expertise in pharmaceutical manufacturing and negotiations of agreements with multinational companies.

 

Alexander D.G. Reid (age 73, Director of CardioGenics since 1998). Mr. Reid has been in the financial community with experience in public and private companies for over 30 years. He has held numerous positions and board memberships in various financial and non-financial corporations. For many years, Mr. Reid was the author of the market business column in the Financial Post. Through his writing, various business models have been analysed and critiqued.  He has been involved with the Company as a shareholder since 1999; 

 

Linda J. Sterling (age 50, Corporate Secretary of CardioGenics since 2003, Director of CardioGenics since 2009). Ms. Sterling has been in the legal community in the capacity as a Law Clerk with both Stikeman Elliott LLP and Davies Ward Phillips & Vineberg LLP since 1999. She developed expertise with both public and private company legal compliance and has been responsible for CardioGenics' compliance and maintenance of corporate governance since 2001. She is currently in the process of being licensed as a Legal Executive (F.Inst.L.C.O.), with the Institute of Law Clerks of Ontario, of which she is a member. She has held the position of CEO and director of Sterling Studios since 1989.

 

James A. Essex, CA, MBA (age 63, Chief Financial Officer of CardioGenics since 2001) Mr. Essex has been with CardioGenics since 1999. He founded J. Hunter & Associates Inc. in 1990, a private financial consulting firm. Previously, he was a co-owner, President and COO of Calais Investigations, Inc., a private company (from 1993 to 1998), a Vice President of Confederation Trust (1989) and a Vice President of Chemical Bank of Canada (now JP Morgan Chase Bank of Canada) from 1977 through 1987.

 

Board Committees

 

Our Board of Directors does not have standing audit, nominating or compensation committees.  Instead, the functions that might be delegated to such committees are carried out by our entire Board of Directors, to the extent required.  Our Board of Directors anticipates forming one or more of such committees during our 2012 fiscal year.

 

Nomination of Directors

 

There have been no material changes to the procedures by which our security holders may recommend nominees to our Board of Directors.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Under the securities laws of the United States, our directors, executive officers and any person holding more than 10% of our common stock are required to file initial forms of ownership of our common stock and reports of changes in that ownership to the SEC. Specific due dates for these forms have been established, and we are required to disclose in this report any failure to file by these due dates.

 

Based solely on our review of the copies of such forms with respect to fiscal 2011, or written representations from certain reporting persons, to the best of our knowledge, all reports were filed on a timely basis.

30
 

 

Code of Ethics

 

We have adopted a Code of Ethics (our “Code of Ethics”) that applies to our Chief Executive Officer and Chief Financial Officer.  We will provide to any person without charge, upon request, a copy of our Code of Ethics by sending such request to the attention: Yahia Gawad, Chief Executive Officer, CardioGenics Holdings Inc., 6295 Northam Drive, Unit 8, Mississauga, Ontario, L4V 1W8.  The Company will promptly disclose any amendments or waivers to our Code of Ethics on Form 8-K.

 

Item 11. EXECUTIVE COMPENSATION

 

As a “smaller reporting company,” CardioGenics has elected to follow scaled disclosure requirements for smaller reporting companies with respect to Part III, Item 11 – Executive Compensation. Under the scaled disclosure obligations, Cardiogenics is not required to provide CompensationDiscussion and Analysis and certain other tabular and narrative disclosures relating to executive compensation. Nor is CardioGenics required to quantify payments due to the named executives upon termination of employment. Management believes that the scaled disclosure for the Company’s executive compensation policy and practices is appropriate because CardioGenics is small for a publicly-traded company, has only three named executives and has a relatively simple compensation policy and structure that has not changed in the last fiscal year.

 

Summary Compensation Table

The following table provides information concerning compensation of CardioGenics’ named executives for CardioGenics’ last two completed fiscal years ending October 31, 2010 and 2011.

 

Name and     Salary   Stock Awards   Total  
Principal Position Year   ($)   ($)   ($)  
                 
Dr. Yahia Gawad 2011     152,238 (1)       152,238  
Chief Executive Officer 2010     143,968 (1)       143,968  
                     
James A. Essex 2011     36,537 (1)       36,537  
Chief Financial Officer 2010     35,881 (1)       35,881  
                     
Linda J. Sterling 2011     30,448 (1)       30,448  
Corporate Secretary 2010     45,590 (1)       45,590  

 

  (1) Cash compensation is stated in the table in U.S. dollars. To the extent any cash compensation was paid in Canadian dollars, it has been converted into U.S. dollars based on the average Canadian/U.S. dollar exchange rate for the years ended October 31, 2011 and October 31, 2010.

 

Other Benefit Plans

 

The Company has no defined benefit or actuarial pension plans.

 

Employment Agreements

 

We currently do not have written employment agreements with any of our current officers or executive personnel, except for Dr. Yahia Gawad, who has a 3 year employment agreement with CardioGenics Holdings Inc. with an annual salary of $150,000, health and dental insurance coverage on terms not less favorable than the health insurance coverage to be offered by the Company to its employees, performance bonuses in the form of cash and stock options to be proposed to the Board of Directors on an annual basis, non-compete agreement for 24 months after effective takeover and 18 months full salary severance pay and benefit for firing without cause.  Further, for each calendar year of the Term he will be entitled to five (5) weeks paid vacation.  Also, he will be eligible for Stock Option incentives to the executive as approved by the Board of Directors.

31
 

 

With respect to our former directors and executives, Messrs. Thomas J. Mazzarisi and Stephen J. Schoepfer, they each received to the date of change in control an annual base salary of $150,000 pursuant to their amended and restated employment agreements.

 

Pursuant to these employment agreements, Messrs. Mazzarisi and Schoepfer were also entitled to the same medical and other benefits, including health and life insurance coverage, as are provided to our other employees.  The agreements also provided that in the event the employment of Messrs. Mazzarisi and Schoepfer are terminated without cause or such executive resigns for good reasons as defined in the employment agreements, they shall be entitled to receive (i) continued medical and life insurance coverage for a period equal to the greater of one year or the number of years and fractions thereof between the date of such termination and the end of the term (the “Severance Period”), (ii) a lump sum cash payment equal to the executive’s highest rate of annual salary in effect during the term multiplied by the Severance Period, (iii) a lump sum cash payment equal to the number of accrued and unused vacation days calculated at the executive’s then current salary rate and (iv) accelerated vesting of all of the executive’s outstanding stock options.  Such cash payments are required to be made within ten days of termination of employment, and shall not be subject to offset amounts earned by the executive in respect of any subsequent employment, nor is the executive required to seek any such subsequent employment.

 

The employment agreements further provided that, immediately prior to a “change in control” (as defined in our 1999 Long-Term Incentive Plan), Messrs. Mazzarisi and Schoepfer were to be granted an option to acquire 100,000 shares of our common stock (subject to equitable adjustments for stock splits, etc.) at an exercise price equal to the fair market value of the average closing bid price for shares of our common stock for the 30 days prior to such change in control, which option shall be fully vested and immediately exercisable in full and expire on a date which is the earlier of ten years from such change in control and three years after termination of employment.  Generally, under our 1999 Long-Term Incentive Plan a “change in control” shall be deemed to have occurred (i) if there is an acquisition of 30% or more of our then outstanding shares of common stock, (ii) Messrs. Mazzarisi and Schoepfer cease for any reason to constitute at least a majority of the members of our Board of Directors, or (iii) a merger, shall have occurred.  However, a change in control shall not be deemed to have occurred if consummation of such a transaction would result in at least 70% of the total voting power represented by our voting securities outstanding immediately after such transaction being beneficially owned by at least 75% of the holders of our outstanding voting securities immediately prior to the transaction, with the voting power of each such continuing holder relative to other such continuing holders not substantially altered in the transaction.

 

As the CardioGenics Acquisition resulted in a “change in control” as described above, Messrs. Mazzarisi and Schoepfer were each granted upon their resignation at the closing an option to acquire 100,000 shares of our common stock at an exercise price of $3.60 per share, in accordance with the terms of their respective employment agreements.  During 2011, all options formerly held by Messrs. Mazzarisi and Schoepfer were re-priced at $0.01 per share and exercised.

 

Director Compensation

 

Non-Employee Directors' Compensation

 

In fiscal 2011 our policy for compensation of non-employee directors was as follows:

 

  1. Non-employee directors do not receive an annual cash base retainer.  

 

  2. At the discretion of the full Board of Directors, nonemployee directors may receive shares of the Company’s common stock. The number and terms of such shares is within the discretion of the full Board of Directors.

 

  3. Directors who are officers or employees of CardioGenics do not receive separate consideration for their service on the Board of Directors.

 

Fiscal Year 2011 Director Compensation Table

 

    Stock Award   Stock Award      
    As Director   (Other)   Total (1)  
Name   $   $   $  
               
J. Neil Tabatznik     0         0  
                   
Alexander D. G. Reid     0         0  

 

  (1) As of October 31, 2011, the aggregate number of shares underlying stock awards granted to each non-employee director was as follows: Mr. Tabatnik (561,648) and Mr. Reid (52,393).
32
 

 

Indemnification of Officers and Directors

 

Our amended and restated Articles of Incorporation provide that we shall indemnify our officers, directors, employees and agents to the full extent permitted by Nevada law.  Our Bylaws include provisions to indemnify our officers and directors and other persons against expenses (including judgments, fines and amounts paid for settlement) incurred in connection with actions or proceedings brought against them by reason of their serving or having served as officers, directors, or in other capacities.  We do not, however, indemnify them in actions in which it is determined that they have not acted in good faith or have acted unlawfully or not in our best interest.  In the case of an action brought by or in the right of us, we shall indemnify them only to the extent of expenses actually and reasonably incurred by them in connection with the defense or settlement of these actions and we shall not indemnify them in connection with any matter as to which they have been found to be liable to us, unless the deciding court determines that, notwithstanding such liability, that person is fairly entitled to indemnity in light of all the relevant circumstances.

 

We do not currently maintain director’s and officer’s liability insurance but may do so in the future.

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors and officers pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND RELATED STOCKHOLDER MATTERS.

 

The following table sets forth certain information regarding the beneficial ownership of our common stock as of January 10, 2012 (except as otherwise indicated) by (i) each person known by us to be the beneficial owner of more than five percent (5%) of our common stock, (ii) each director and nominee to be a director,  (iii) each named executive officer and (iv) all of our directors and executive officers as a group.  Except as otherwise indicated below, each of the persons named in the table has sole voting and investment power with respect to the shares set forth opposite such person’s name.  Unless otherwise indicated the address of each person listed in this table is c/o CardioGenics Holdings Inc., 6295 Northam Drive, Unit 8, Mississauga, Ontario, Canada, L4V 1W8.

 

Name & Address of Beneficial

Owner

 

Number of Shares

Beneficially Owned

    Percentage of Class**  
Yahia Gawad     18,144,652       27.70 %
                 
Alexander D.G. Reid     523,196       *  
                 
J. Neil Tabatznik     2,482,534(1)       3.79 %
                 
Linda J. Sterling     1,501,617       2.29 %
                 
James Essex     398,183       *  
                 
All executive officers and directors as a group (5 persons)     23,050,182       33.78 %

 

* Less than one percent (1%)
** Based on 65,461,135 shares of common stock issued and outstanding and all options and warrants to acquire common stock having been exercised

 

33
 

 

(1) Included 157,178 shares of common stock issuable upon exercise of a warrant

 

Equity Compensation Plan Information

 

The following table summarizes the shares of our common stock authorized for issuance under our equity compensation plans as of October 31, 2011

 

            Number of  
            securities remaining  
  Number of         available for future  
  securities     Weighted average   issuance under  
  to be issued upon     exercise price of   equity compensation  
  exercise of     outstanding   plans (excluding  
  outstanding options,     options, warrants   securities reflected  
  warrants and rights     and rights   In column (a))  
  (a)     (b)   (c)  
Equity compensation plans approved by security holders Not applicable     Not applicable   Not applicable  
               
Equity compensation plans not approved by security holders   $     30,000  
                 
TOTAL       30,000  

 

  (1) The maximum number of shares that may be subject to outstanding awards under our 1999 Long-Term Incentive Plan is 600,000 shares of Common Stock.  Because this limitation applies only to outstanding awards under the plan, as the outstanding options included in column (a) are either exercised, forfeited or expire pursuant to their terms, the number of shares remaining available for future issuance in column (c) shall be increased by the number of shares subject to such option so exercised, forfeited or expired.

 

Our 1999 Long-Term Incentive Plan provides our directors, officers, employees and consultants with the opportunity to participate in our ownership.  Our Board of Directors acts as the committee under the plan which administers the plan, addressing participation, the awards offered and any applicable conditions of exercise.  In making these determinations, our Board of Directors will generally consider the participant’s position and record of service to us.  The Board of Directors may issue options, stock appreciation rights, restricted stock, deferred stock, bonus stock, awards in lieu of cash obligations, dividend equivalents and other stock based awards, all subject to terms and conditions to be set by the Board of Directors.  The plan also contains standard provisions dealing with matters such as adjustment of the number of shares subject to options and covered by the plan in additions to amendment and termination of the plan.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

As a smaller reporting company, CardioGenics is required to follow the scaled disclosure requirements with respect to this Part III, Item 13 – CertainRelationships and Related Transactions, and Director Independence . The disclosures related to review of related person transactions are not applicable to smaller reporting companies

 

Certain Relationships and Related Party Transactions

 

During the year ended October 31, 2011, the Company repaid advances from a director totaling approximately $15,149 bearing interest at 0% per annum.

 

Director Independence

 

The Board of Directors currently consists of four members, two of whom are “independent” as defined under applicable rules of the SEC and The NASDAQ Stock Market LLC. The two independent members of the Board of Directors are Neil Tabatznik, and Alexander D. G. Reid.


34
 

 

For a director to be considered independent, the Board must determine that the director has no relationship which, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

 

KPMG LLP has been appointed as our independent public accountants for the year ended October 31, 2011 by unanimous approval of the Board of Directors. KPMG LLP is the successor to our former independent auditors J.H. Cohn LLP.

 

J.H. Cohn LLP had served as our independent auditors since August 31, 2009. The appointment of J. H. Cohn LLP as our independent public accountants was unanimously approved by the Board of Directors. J.H. Cohn LLP is the successor to our former independent auditors, BDO Dunwoody LLP (“BDO”).

BDO served as our independent auditors from December 1, 2007 until August 31, 2009.

 

The following table sets forth the aggregate fees paid by CardioGenics for the fiscal years ended October 31, 2011 and 2010 to our independent auditors:

 

    Fiscal Year     Fiscal Year  
    Ended     Ended  
    October     October  
    2011     2010  
             
Audit fees   $ 130,000 (1)   $ 66,090  
Audit related fees   $ 53,173 (2)   $ 46,728 (2)
Tax fees (3)   $ 0 (3)   $ 0 (3)
All other fees   $ 0     $ 0  

 

(1) Represents estimated audit fees for the fiscal year ended October 31, 2011.
(2) Represents charges of J.H. Cohn LLP, CardioGenics’ auditor in the fiscal years ended October 31, 2011and 2010 for review of interim financial statements.
(3) J.H. Cohn LLP or KPMG LLP did not provide and did not bill for any tax services.

 

All Other Fees

 

There were no other fees billed by KPMG LLP or J.H. Cohn LLP in the years ended October 31, 2011 or October 31, 2010.

 

Pre-Approval Policies and Procedures

 

The Board of Directors is required to pre-approve the rendering by our independent auditor of audit or permitted non-audit services. The Board of Directors pre-approved all of the services rendered by J.H. Cohn LLP for the audit of the consolidated financial statements included in our Annual Reports on Form 10-K and reviews of consolidated financial statements included in our Quarterly Reports on Form 10-Q.

 

The services provided for in 2011 were 53% audit services and 47% audit related services.  The services provided above for 2010 were 56% audit services and 44% audit related services.


35
 

 

PART III

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 

Exhibits

 

The following Exhibits are filed as part of this Annual Report on Form 10-K or incorporated by reference.

 

Exhibit No.   Description
3.1   Amended and Restated Articles of Incorporation of Registrant.  Incorporated by reference to the Registrant’s Form 10-QSB filed with the SEC on June 19, 2006.
     
3.2   Bylaws of Registrant.  Incorporated by reference to the Registrant’s Form SB-2 filed with the SEC on September 30, 1999.
     
3.3   Certificate of Designation of Series 1 Preferred Stock of Registrant. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on July 24, 2009.
     
3.4   Articles of Amendment of CardioGenics ExchangeCo Inc. effective July 14 2009 and Articles of Incorporation of CardioGenics ExchangeCo Inc. Effective May 22, 2009
     
3.5   Certificate of Amendment to Articles of Incorporation of Registrant. Incorporated by reference to the Registrant’s Form DEF 14C filed with the SEC on September 9, 2009.
     
3.6   Certificate of Change of CardioGenics Holdings Inc. Effective June 18, 2010. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on June 23, 2010.
     
4.1   Form of Common Stock Certificate.  Incorporated by reference to the Registrant’s Form 10-KSB filed with the SEC on November 8, 2005.
     
4.2   Form of Series 2 Class B Stock Certificate. Incorporated by reference to the Registrant’s Form 10-KSB filed with the SEC on November 8, 2005.
     
4.3   Securities Purchase Agreement, effective May 25, 2006, with YA Global. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on June 1, 2006.
     
4.4   Letter Agreement, dated January 31, 2008, relating to the conversion of the remaining principal balance of the convertible secured debentures.  Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on February 6, 2008.
     
4.5   Warrant No. CCP-1 for 2,000,000 shares of common stock issued to YA Global, effective May 25, 2006. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on June 1, 2006.
     
4.6   Warrant No. CCP-2 for 2,000,000 shares of common stock issued to YA Global, effective May 25, 2006.  Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on June 1, 2006.
     
4.7   Warrant No. CCP-3 for 2,000,000 shares of common stock issued to YA Global, effective May 25, 2006.  Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on June 1, 2006.
     
4.8   Warrant No. CCP-4 for 3,000,000 shares of common stock issued to YA Global, effective May 25, 2006.  Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on June 1, 2006.
     
4.9   Warrant No. CCP-5 for 3,000,000 shares of common stock issued to YA Global, effective May 25, 2006.  Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on June 1, 2006.
     
4.10   Letter Agreement, amending Warrant No. CCP-4. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on October 3, 2008.

 

36
 

 

Exhibit No.   Description
4.11   Investor Registration Rights Agreement, effective May 25, 2006, with YA Global. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on June 1, 2006.
     
10.1   Non-Binding Letter of Intent, dated October 1, 2008, by and among the Registrant, BlueCreek, e2 Business and YA Global.  Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on October 3, 2008.
     
10.2   1999 Long-Term Incentive Plan, as amended.  Incorporated by reference to Exhibit [  ] to the Registrant’s Form S-8 filed with the SEC on May 1, 2002.
     
10.3   Amended and Restated Employment Agreement, dated August 31, 2001, between Thomas J. Mazzarisi and Registrant.  Incorporated by reference to Exhibit 10.21 in Amendment No. 1 to the Registrant’s Form SB-2 filed with the SEC on September 26, 2001.
     
10.4   Amended and Restated Employment Agreement, dated August 31, 2001, between Stephen J. Schoepfer and Registrant.  Incorporated by reference to Exhibit 10.20 in Amendment No. 1 to the Registrant’s Form SB-2 filed with the SEC on September 26, 2001.
     
10.5   Amendment to Amended and Restated Employment Agreement, dated as of November 3, 2005, between Registrant and Thomas J. Mazzarisi.  Incorporated by reference to the Registrant’s Form 10-KSB filed with the SEC on November 8, 2005.
     
10.6   Amendment to Amended and Restated Employment Agreement, dated as of November 3, 2005, between Registrant and Stephen J. Schoepfer.  Incorporated by reference to the Registrant’s Form 10-KSB filed with the SEC on November 8, 2005.
     
10.7   Amendment to Amended and Restated Employment Agreement, dated as of November 12, 2007, by and between Registrant and Thomas J. Mazzarisi.  Incorporated by reference to Exhibit 10.6 of Registrant’s Form 10-K filed with the SEC on November 13, 2008.
     
10.8   Amendment to Amended and Restated Employment Agreement, dated as of November 12, 2007, by and between Registrant and Stephen J. Schoepfer.  Incorporated by reference to Exhibit 10.7 of the Registrant’s Form 10-K filed with the SEC on November 13, 2008
     
10.9   Extension of Amended and Restated Employment Agreement dated as of November 12, 2008 between registrant and Thomas J. Mazzarisi. Incorporated by reference to Exhibit 10.9 of the Registrant’s Form 10-K filed with the SEC on November 13, 2008.
     
10.10   Extension of Amended and Restated Employment Agreement dated as of November 12, 2008 between registrant and Stephen J. Schoepfer. Incorporated by reference to Exhibit 10.10 of the Registrant’s Form 10-K filed with the SEC on November 13, 2008.
     
10.11  

Consulting Agreement, dated November 12, 2007, between the Registrant and Walsh Organization, Inc.

Incorporated by reference to Exhibit 10.31 of the Registrant’s Annual Report on Form 10-KSB filed November 13, 2003.

     
10.12   Power of Attorney and Contingent Fee Contract, dated June 14, 2002, among the Registrant, Gary Valinoti and the Law Firm of O’Quinn, Laminack & Pirtle. Incorporated by reference to Exhibit 10.32 of the Registrant’s Annual Report on Form 10-KSB filed November 13, 2003.
     
10.13   Subscription Agreement, dated December 10, 2002, between the Registrant and Bay Point Investment Partners LLC. Incorporated by reference to the Registrant’s Registration Statement on Form SB-2 filed on January 9, 2003.
     
10.14   Placement Agent Agreement, dated December 10, 2002, between the Registrant and RMC 1 Capital Markets, Inc. Incorporated by reference to the Registrant’s Registration Statement on Form SB-2 filed on January 9, 2003.

 

37
 

 

Exhibit No.   Description
10.15   Placement Agent Agreement, dated as of June 19, 2003, between the Registrant and RMC 1 Capital Markets, Inc., as amended on August 12, 2003. Incorporated by reference to the Registrant’s Current Report on Form 8-K filed on August 13, 2003.
     
10.16   Subscription Agreement, dated as of June 19, 2003, between the Registrant and Bay Point Investment Partners LLC, as amended on August 12, 2003. Incorporated by reference to the Registrant’s Current Report on Form 8-K filed on August 13, 2003.
     
10.17   Subscription Agreement, dated as of September 25, 2003, between the Registrant and Kuekenhof Equity Fund L.P. Incorporated by reference to Exhibit 10.39 of the Registrant’s Form 10-KSB filed with the SEC on November 13, 2003.
     
10.18   Non-Circumvention/Non-Disclosure Agreement, dated as of January 1, 2004 between Flow Capital Advisors Inc. and the Registrant. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on July 25, 2007.
     
10.19   Finder’s Fee Agreement, dated as of January 5, 2004, between the Registrant and Flow Capital Advisors, Inc. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on January 20, 2004.
     
10.20   Finder’s Fee Agreement, dated as of March 14, 2005, by and between the Registrant and Flow Capital Advisors, Inc. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on July 25, 2007.
     
10.21   Irrevocable Transfer Agent Instructions, effective May 25, 2006, between the Registrant and YA Global. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on June 1, 2006.
     
10.22   Letter, dated as of June 17, 2008, from Cryptometrics regarding termination of the agreement and plan of merger between the Registrant and Cryptometrics. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on June 18, 2008.
     
10.23   Stand-By Equity Distribution Agreement dated March 12, 2009 between Registrant and YA Global Master SPV Ltd. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on March 13, 2009.
     
10.24   Registration Rights Agreement dated March 12, 2009 between Registrant and YA Global Master SPV Ltd. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on March 13, 2009.
     
10.23   Share Purchase Agreement dated May 22, 2009 between Registrant, CardioGenics ExchnageCo Inc., CardioGenics Inc. And Yahia Gawad, Principal Shareholder of CardioGenics Inc.
     
10.24   Voting and Exchange Trust Agreement dated July 6, 2009 among Registrant, CardioGenics ExchangeCo Inc. and Weirfoulds LLP. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on July 6, 2009.
     
10.25   Support Agreement dated July 6, 2009 between Registrant and CardioGenics ExchangeCo Inc. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on July 6, 2009.
     
10.26   Agreement dated September 10, 2009 between Registrant and The Investor’s Relations Group, Inc. by reference to the Registrant’s Form 8-K filed with the SEC on September 11, 2009.
     
10.27   Agreement dated September 28, 2009 between Registrant and Gilford Securities Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on October 2, 2009.
     
10.28   Retainer Agreement dated January 20, 2010 between Registrant and Wolf, Axelrod & Weinberger Associates LLC. Incorporated by reference to the Registrant’s Form 10-K filed with the SEC on February 16, 2010.
     
10.29   Letter of Agreement dated January 18, 2010 between Registrant and The Investor Relations Group, Inc. Incorporated by reference to the Registrant’s Form 10-K filed with the SEC on February 16, 2010.

 

38
 

 

Exhibit No.   Description
10.30   Employment agreement dated July 31, 2009 between Registrant and Dr. Yahia Gawad. Incorporated by reference to the Registrant’s Form 10-K filed with the SEC on February 16, 2010.
     
10.31   LLC Membership Interest Purchase Agreement dated February 10, 2010 between Registrant and Rothcove Partners LLC. Incorporated by reference to the Registrant’s Form 10-K filed with the SEC on February 16, 2010.
     
10.31   Lock-Up Agreement dated March 15, 2010 among Yahia Gawad, CardioGenics Holdings Inc., CardioGenics ExchangeCo Inc. and Weirfoulds LLP. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on March 16, 2010.
     
10.32   Letter Agreement dated March 19, 2010 between Registrant and YA Global Master SPV Ltd. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on March 22, 2010.
     
10.33   Form of Lock-Up Agreements entered into by certain members of the Board of the Directors of Registrant and certain other stockholders with respect to their “Exchangeable Shares.” Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on March 25, 2010.
     
10.34   Form of Lock-Up Agreements entered into by certain members of the Board of the Directors of Registrant and certain other stockholders with respect to their shares of the Registrant’s common stock. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on March 25, 2010.
     
10.35   Form of Subscription Agreements for Sale of Unregistered Securities made on November 3, 2010. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on December 4, 2010.
     
10.36   Letter Agreement dated December 21, 2010 entered into between CardioGenics Holdings Inc. and Chandra Panchal. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on December 22, 2010.
     
10.37   Redemption Notice for Series 2 Class B Common Stock dated February 25, 2011 and Redemption Notice for Series 3 Class B Common Stock dated February 25, 2011. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on March 2, 2011.
     
10.38   Intellectual Property Assignment & License Agreement dated June 21, 2011 between CardioGenics Inc., an Ontario corporation and Luxspheres Inc., an Ontario corporation. Incorporated by reference to the Registrant’s Form 8-K filed with the SEC on June 22, 2011.
     
14.1   Code of Ethics.  Incorporated by reference to the Registrant’s Form 10-KSB filed with the SEC on November 13, 2003.
     
21.1   Subsidiaries of Registrant. Incorporated by reference to the Registrant’s Form 10-K filed with the SEC on January 31, 2011.
     
23.1   Consent of KPMG LLP
     
23.2   Consent of J.H. Cohn LLP*
     
23.3   Consent of BDO Dunwoody LLP*
     
31.1   Section 302 Certification of Chief Executive Officer*
     
31.2   Section 302 Certification of Chief Financial Officer*
     
32.1   Section 906 Certification of Chief Executive Officer and Chief Financial Officer*

 

*Filed herewith

39
 

 

Consolidated Financial Statements

 

Report of Independent Registered Public Accounting Firm F-1
   
Report of Independent Registered Public Accounting Firm F-2
   
Report of Independent Registered Public Accounting Firm F-3
   
Consolidated Balance Sheets F-4
   
Consolidated Statements of Operations F-5
   
Consolidated Statements of Equity (Deficiency) F-6-12
   
Consolidated Statements of Cash Flows F-13
   
Notes to Consolidated Financial Statements F-14-31

 

40
 

 

CardioGenics Holdings Inc.
(A Development Stage Company)
Report of Independent Registered Public Accounting Firm

 

To the Board of Directors and Stockholders of CardioGenics Holdings Inc.

 

We have audited the accompanying consolidated balance sheet of CardioGenics Holdings Inc. (a development stage company) as of October 31, 2011, and the related consolidated statements of operations, changes in equity (deficiency) and cash flows for the year then ended and for the period from November 20, 1997 (date of inception) to October 31, 2011. These consolidated financial statements are the responsibility of CardioGenics Holdings Inc.'s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. The cumulative statements of operations, changes in equity (deficiency) and cash flows for the period from November 20, 1997 (date of inception) to October 31, 2011 include amounts for the period from November 20, 1997 (date of inception) to October 31, 2010, which were audited by other auditors whose unqualified reports, which contained an explanatory paragraph related to the Company’s ability to continue as a going concern, have been furnished to us, and our opinion, insofar as it relates to the amounts included for the period November 20, 1997 (date of inception) through October 31, 2010 is based solely on the reports of other auditors.

 

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

 

In our opinion, based on our audits and the reports of other auditors, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of CardioGenics Holdings Inc. as of October 31, 2011, and the results of its operations and its cash flows for the years ended October 31, 2011, in conformity with U.S. generally accepted accounting principles.

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in note 3 to the consolidated financial statements, the Company has incurred losses from operations and has experienced negative cash flows from operations since inception which raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in note 3. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

As discussed in note 2 to the consolidated financial statements, the 2011 consolidated financial statements have been restated to correct for misstatements.

 

/s/ KPMG LLP

Chartered Accountants, Licensed Public Accountants

 

Toronto, Canada

April 13, 2012

 

F-1
 

 

CardioGenics Holdings Inc.
(A Development Stage Company)
Report of Independent Registered Public Accounting Firm

 

To the Board of Directors and Stockholders

CardioGenics Holdings, Inc.

 

We have audited the accompanying consolidated balance sheet of CardioGenics Holdings Inc. (a development stage company) as of October 31, 2010, and the related consolidated statements of operations, changes in equity (deficiency) and cash flows for the year then ended and for the period from November 20, 1997 (date of inception) to October 31, 2010. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.  The financial statements of CardioGenics, Inc. for the period from November 20, 1997 to October 31, 2008 were audited by other auditors whose report dated July 29, 2009 expressed an unqualified opinion on those statements with an explanatory paragraph relating to the Company’s ability to continue as a going concern.  Our opinion on the consolidated statements of operations, changes in equity (deficiency) and cash flows for the period from November 20, 1997 (date of inception) to October 31, 2010, insofar as it relates to amounts for prior periods through October 31, 2008, is based solely on the report of the other auditors.

 

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of CardioGenics Holdings, Inc. as of October 31, 2010, and their results of operations and cash flows for the year then ended, and for the period from November 20, 1997 (date of inception) to October 31, 2010, in conformity with accounting principles generally accepted in the United States of America.

 

The consolidated financial statements referred to above have been prepared assuming that the Company will continue as a going concern. As further discussed in Note 3 to the consolidated financial statements, the Company's operations have generated recurring losses and negative cash flows from operating activities. Such matters raise substantial doubt about the Company's ability to continue as a going concern. Management's plans concerning these matters are also described in Note 3. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

 

/s/ J.H. Cohn LLP

Roseland, New Jersey

January 31, 2011

 

F-2
 

 

CardioGenics Holdings Inc.
(A Development Stage Company)
Report of Independent Registered Public Accounting Firm

 

To the Directors and Shareholders of

CardioGenics Holdings Inc. (formerly CardioGenics Inc.)

(A Development Stage Company)

 

We have audited the accompanying consolidated balance sheet of CardioGenics Holdings Inc. (formerly CardioGenics Inc.) (a development stage company) as at October 31, 2008 and the related consolidated statements of operations, changes in equity (deficit) and cash flows for the year ended October 31, 2008.  These consolidated financial statements are the responsibility of the Company’s management.  Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

 

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.  The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.  Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.  Accordingly we express no such opinion.  An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements and assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audit provides a reasonable basis for our opinion.

 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of CardioGenics Holdings Inc. (formerly CardioGenics Inc.) (a development stage company) as at October 31, 2008 and the results of its operations and its cash flows for the year ended October 31, 2008 in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.  As discussed in Note 3 to the financial statements, the Company has suffered recurring net losses and negative cash flows from operations.  These matters raise substantial doubt about the Company’s ability to continue as a going concern.  Management’s plans regarding these matters are also described in Note 3.  The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

(Signed) “BDO Canada LLP”

 

Chartered Accountants, Licensed Public Accountants

 

Toronto, Ontario

July 29, 2009


F-3
 

 

CardioGenics Holdings Inc.
(A Development Stage Company)
Consolidated Balance Sheets

 

    October 31,     October 31,  
    2011     2010  
    (restated)        
             
Assets            
             
Current Assets            
Cash and Cash Equivalents   $ 669,202     $ 1,844,752  
Accounts Receivable     9,002      
Share Subscriptions Receivable         115,000  
Deposits and Prepaid Expenses     51,541       89,774  
Refundable Taxes Receivable     35,191       21,959  
Government Grants and Investment Tax Credits Receivable   187,497       156,482  
      952,433       2,227,967  
Long term Assets                
Property and Equipment, net     82,308       87,465  
Patents, net     130,732       170,703  
Prepaid Consulting Contract            
      213,040       258,168  
Total Assets   $ 1,165,473     $ 2,486,135  
                 
Liabilities and Equity                
                 
Current Liabilities                
Accounts Payable and Accrued Expenses   $ 596,692     $ 523,155  
Due to Director         15,149  
Current Portion of Capital Lease Obligation     25,711       20,992  
Funds Held in Trust for Redemption of Class B Common Shares     4      
      622,407       559,296  
                 
Long Term Liabilities                
Capital Lease Obligation, net of current portion     2,630       20,881  
Total Liabilities     625,037       580,177  
                 
Mandatorily redeemable Class B common stock; par value $.00001 per share: 400,000 shares designated as series 2; 381,749 shares issued and outstanding         4  
40,000 shares designated as series 3; 21,500 shares issued and outstanding        
          4  
                 
Commitments and contingencies                
Total Equity                
Preferred stock; par value $.0001 per share, 5,000,000 shares authorized, none issued        
Common stock; par value $.00001 per share; 65,000,000 shares authorized, 31,237,262 and 28,620,257 common shares and 24,388,904 and 24,388,904 exchangeable shares issued and outstanding as at October 31, 2011 and 2010, respectively     540       514  
                 
Additional paid-in capital     41,774,001       37,441,728  
                 
Deficit accumulated during development stage     (40,731,174 )     (35,006,558 )
                 
Accumulated other comprehensive loss     (173,407 )     (237,508 )
                 
Total equity attributable to CardioGenics Holdings Inc.     869,960       2,198,176  
Non-Controlling Interest     (329,524 )     (292,222 )
Total Equity     540,436       1,905,954  
Total liabilities and equity   $ 1,165,473     $ 2,486,135  

 

See accompanying notes to consolidated financial statements.

 

F-4
 

 

CardioGenics Holdings Inc.
(A Development Stage Company)
Consolidated Statements of Operations
For the Years Ended October 31, 2011 and 2010 and
Cumulative from November 20, 1997 (Date of Inception) to October 31, 2011

 

                Cumulative  
                From  
                November 20,  
                1997  
                (Date of  
    For the Years Ended     Inception) to  
    October 31,     October 31,  
    2011     2010     2011  
    (restated)           (restated)  
                   
Revenue   $ 8,876           $ 8,876  
                         
Operating Expenses                        
Depreciation of Property and Equipment     20,399       20,932       201,439  
Amortization of Patent Application Costs     5,207       3,023       12,411  
Write-off of Patent Application Costs     55,549       105,345       214,625  
General and Administrative     3,398,960       1,246,887       7,675,068  
Write-off of Goodwill                 12,780,214  
Research and Product Development, net of Investment Tax Credits     426,007       605,658       3,627,380  
Cost of Settlement of Lawsuit     1,753,800             1,753,800  
Total operating expenses     5,659,922       1,981,845       26,264,937  
Operating Loss     (5,651,046 )     (1,981,845 )     (26,256,061 )
                         
Other Expenses                        
Interest Expense and Bank Charges     20,135       30,166       2,136,636  
Loss on Change in Value of Derivative Liability                 12,421,023  
Loss on Foreign Exchange Transactions     90,737       104,182       209,265  
Total other expenses     110,872       134,348       14,766,924  
                         
Loss from Continuing Operations Before Income Tax     (5,761,918 )     (2,116,193 )     (41,022,983 )
                         
Discontinued Operations                        
Gain on Sale of Subsidiary           90,051       90,051  
Loss from Discontinued Operations           (12,355 )     (127,762 )
Net Loss     (5,761,918 )     (2,038,497 )     (41,060,696 )
Net Loss Attributable to Non-Controlling Interest     37,302       14,225       329,524  
Net Loss Attributable to CardioGenics Holdings Inc.   $ (5,724,616 )   $ (2,024,272 )   $ (40,731,174 )
                         
Basic and Fully Diluted Net Loss per Common Share   $ (0.11 )   $ (0.04 )        
Basic and Fully Diluted Net Loss per Common Share                        
From Discontinued Operations   $ 0.00     $ 0.00          
                         
Weighted-average number of Common Shares     54,167,687       49,624,916          

 

See accompanying notes to consolidated financial statements. 

F-5
 

 

CardioGenics Holdings Inc.
(A Development Stage Company)
Consolidated Statements of Changes in Equity (Deficiency)
For the year ended October 31, 2011

 

                      Deficit                
                      Accumulated                
                      During   Accumulated          
                Additional     the   Other         Total  
    Common Stock     Paid-in     Development   Comprehensive     Noncontrolling   Equity  
    Shares     Amount     Capital     Stage   Loss     Interest   (Deficiency)  
                                       
Issuance of common shares for cash November 1998     1,592,732     $ 16     $ (15 )                 $ 1  
Issuance of common shares for cash December 1998, $.00     796,366       8       35,028                     35,036  
Issuance of common shares for cash March 1998, $.00     551,611       6       24,442                     24,448  
Issuance of common shares for cash April 1998, $.00     12,986,611       130       5,573                     5,703  
Issuance of common shares for cash May 1998, $.01     210,249       2       17,297                     17,299  
Issuance of common shares for cash August 1998, $.00     2,787,281       28       200                     228  
Issuance of common shares for cash September 1998, $.01     84,100       1       6,570                     6,571  
Issuance of common shares for cash October 1998, $.01     31,949             2,500                     2,500  
Comprehensive Income (Loss)                                              
Net Loss                             (81,208 )             (81,208 )
Other Comprehensive Income (Loss)                                                
Currency Translation Adjustment                                 (2,096         (2,096 )
Total Comprehensive Income (Loss)                             (81,208 ) (2,096         (83,304 )
Balance at October 31, 1998     19,040,899     $ 191     $ 91,595     $ (81,208 ) $        (2,096 $   $ 8,482  

 

                      Deficit                    
                      Accumulated                    
                      During     Accumulated            
                Additional     the     Other           Total  
    Common Stock     Paid-in     Development     Comprehensive     Noncontrolling     Equity  
    Shares     Amount     Capital     Stage     Loss     Interest     (Deficiency)  
                                           
Balance November 1, 1998     19,040,899     $ 191     $ 91,595     $ (81,208 )   $ (2,096 )   $     $ 8,482  
Issuance of common shares for cash November 1998, $.01     32,066             2,500                               2,500  
Issuance of common shares for cash February 1999, $.01     159,273       2       14,287                               14,289  
Commission paid on issuance of common stock for cash February 1999                     (935 )                             (935 )
Issuance of common shares for cash March 1999, $.01     278,728       3       24,707                               24,710  
Commission paid on issuance of common stock for cash March 1999                     (1,647 )                             (1,647 )
Issuance of common shares for cash to minority shareholders April 1999, $.01                 10,707                               10,707  
Commission paid on issuance of common stock for cash April 1999                     (627 )                             (627 )
Issuance of common shares for cash April 1999, $.01     39,818             3,814                               3,814  
Commission paid on issuance of common stock for cash April 1999                     (314 )                             (314 )
Issuance of common shares for cash July 1999, $.01     119,455       1       10,073                               10,074  
Issuance of common shares for cash August 1999, $.01     119,455       1       10,045                               10,046  
Net loss attributable to noncontrolling interest                                             (604 )     (604 )
Comprehensive Income (Loss)                                                        
Net Loss attributable to CardioGenics Holdings Inc.                             (100,141 )                     (100,141 )
Other Comprehensive Income (Loss)                                                        
Currency Translation Adjustment                                     (3,489 )             (3,489 )
Total Comprehensive Income (Loss)                             (100,141 )     (3,489 )             (103,630 )
Balance at October 31, 1999     19,789,694     $ 198     $ 164,205     $ (181,349 )   $ (5,585 )   $ (604 )   $ (23,135 )

 

See accompanying notes to consolidated financial statements. 

F-6
 

 

CardioGenics Holdings Inc.
(A Development Stage Company)
Consolidated Statements of Changes in Equity (Deficiency)
For the year ended October 31, 2011

 

                      Deficit                    
                      Accumulated                    
                      During     Accumulated            
                Additional     the     Other           Total  
    Common Stock     Paid-in     Development     Comprehensive     Noncontrolling     Equity  
    Shares     Amount     Capital     Stage     Loss     Interest     (Deficiency)  
                                           
Balance November 1, 1999     19,789,694     $ 198     $ 164,205     $ (181,349 )   $ (5,585 )   $ (604 )   $ (23,135 )
Issuance of common shares for cash November 1999, $.03     318,546       3       99,997                               100,000  
Issuance of common shares for minority shareholders as employee compensation December 1999, $.03                 3,396                               3,396  
Issuance of common shares for cash March 2000, $.03     167,237       2       43,124                               43,126  
Issuance of common shares for minority shareholders for cash March, 2000, $.03                 25,330                               25,330  
Issuance of common shares for cash April 2000, $.03     23,891             6,128                               6,128  
Loan Payable plus interest exchanged for shares July 2000, $.03     356,772       4       111,996                               112,000  
Issuance of common shares for minority shareholders as employee compensation October 2000, $.03                 6,611                               6,611  
Issuance of stock options in exchange for services rendered October 2000                   11,570                               11,570  
Net loss attributable to noncontrolling interest                                             (1,840 )     (1,840 )
Comprehensive Income (Loss)                                                        
Net Loss attributable to CardioGenics Holdings Inc.                             (152,525 )                     (152,525 )
Other Comprehensive Income (Loss)                                                        
Currency Translation Adjustment                                     921               921  
Total Comprehensive Income (Loss)                             (152,525 )     921               (151,604 )
Balance at October 31, 2000     20,656,140     $ 207     $ 472,357     $ (333,874 )   $ (4,664 )   $ (2,444 )   $ 131,582  

 

                      Deficit                    
                      Accumulated                    
                      During     Accumulated            
                Additional     the     Other           Total  
    Common Stock     Paid-in     Development     Comprehensive     Noncontrolling     Equity  
    Shares     Amount     Capital     Stage     Loss     Interest     (Deficiency)  
                                           
Balance November 1, 2000     20,656,140     $ 207     $ 472,357     $ (333,874 )   $ (4,664 )   $ (2,444 )   $ 131,582  
Issuance of common shares as employee compensation October 2001, $.03     2,410             925                               925  
Issuance of common share for minority shareholders as employee compensation October 2001, $.03                 6,169                               6,169  
Issuance of  stock options in exchange for services rendered October 2001                 22,269                               22,269  
Net loss attributable to noncontrolling interest                                             (1,500 )     (1,500 )
Comprehensive Income (Loss)                                                        
Net Loss attributable to CardioGenics Holdings Inc.                             (114,761 )                     (114,761 )
Other Comprehensive Income (Loss)                                                        
Currency Translation Adjustment                                     (10,528 )             (10,528 )
Total Comprehensive Income (Loss)                             (114,761 )     (10,528 )             (125,289 )
Balance at October 31, 2001     20,658,550     $ 207     $ 501,720     $ (448,635 )   $ (15,192 )   $ (3,944 )   $ 34,156  

 

                      Deficit                    
                      Accumulated                    
                      During     Accumulated            
                Additional     the     Other           Total  
    Common Stock     Paid-in     Development     Comprehensive     Noncontrolling     Equity  
    Shares     Amount     Capital     Stage     Loss     Interest     (Deficiency)  
                                           
Balance November 1, 2001     20,658,550     $ 207     $ 501,720     $ (448,635 )   $ (15,192 )   $ (3,944 )   $ 34,156  
Issuance of common shares for cash June 2002, $.03     1,051,211       11       319,011                               319,022  
Issuance of common shares to minority shareholders for cash July 2002, $.03                 3,235                               3,235  
Issuance of common shares for cash September 2002, $.03     20,957             6,345                               6,345  
Issuance of common shares for minority shareholders as employee compensation October 2002, $.03                 9,505                               9,505  
Issuance of stock options in exchange for services rendered October 2002                 70,518                               70,518  
Net loss attributable to noncontrolling interest                                             (2,243 )     (2,243 )
Comprehensive Income (Loss)                                                        
Net Loss attributable to CardioGenics Holdings Inc.                             (156,214 )                     (156,214 )
Other Comprehensive Income (Loss)                                                        
Currency Translation Adjustment                                     (11,506 )             (11,506 )
Total Comprehensive Income (Loss)                             (156,214 )     (11,506 )             (167,720 )
Balance at October 31, 2002     21,730,718     $ 218     $ 910,334     $ (604,849 )   $ (26,698 )   $ (6,187 )   $ 272,818  

 

See accompanying notes to consolidated financial statements. 

F-7
 

 

CardioGenics Holdings Inc.
(A Development Stage Company)
Consolidated Statements of Changes in Equity (Deficiency)
For the year ended October 31, 2011

 

                      Deficit                    
                      Accumulated                    
                      During     Accumulated            
                Additional     the     Other           Total  
    Common Stock     Paid-in     Development     Comprehensive     Noncontrolling     Equity  
    Shares     Amount     Capital     Stage     Loss     Interest     (Deficiency)  
                                           
Balance November 1, 2002     21,730,718     $ 218     $ 910,334     $ (604,849 )   $ (26,698 )   $ (6,187 )   $ 272,818  
Issuance of common shares for cash May 2003, $.03     28,292             9,871                               9,871  
Issuance of common shares for minority shareholders for cash May 2003 $.03                 10,967                               10,967  
Issuance of warrants in conjunction with convertible debentures September 2003                     358,406                               358,406  
Issuance of common shares as employee compensation October 2003, $.04     56,584       1       20,421                               20,422  
Issuance of common shares for minority shareholders as employee compensation October 2003, $.04                 7,564                               7,564  
Issuance of stock options in exchange for services rendered October 2003                 23,580                               23,580  
Net loss attributable to noncontrolling interest                                             (3,825 )     (3,825 )
Comprehensive Income (Loss)                                                        
Net Loss attributable to CardioGenics Holdings Inc.                             (228,993 )                     (228,993 )
Other Comprehensive Income (Loss)                                                        
Currency Translation Adjustment                                     42,957               42,957  
Total Comprehensive Income (Loss)                             (228,993 )     42,957               (186,036 )
Balance at October 31, 2003     21,815,594     $ 219     $ 1,341,143     $ (833,842 )   $ 16,259     $ (10,012 )   $ 513,767  

 

                      Deficit                    
                      Accumulated                    
                      During     Accumulated            
                Additional     the     Other           Total  
    Common Stock     Paid-in     Development     Comprehensive     Noncontrolling     Equity  
    Shares     Amount     Capital     Stage     Loss     Interest     (Deficiency)  
                                           
Balance November 1, 2003     21,815,594     $ 219     $ 1,341,143     $ (833,842 )   $ 16,259     $ (10,012 )   $ 513,767  
Issuance of warrants in conjunction with convertible debentures September 2004                     152,628                               152,628  
Issuance of common shares as employee compensation October 2004, $.04     123,646       1       47,316                               47,317  
Issuance of common shares as directors' compensation October 2004, $.04     157,177       2       60,147                               60,149  
Issuance of stock options in exchange for services rendered October 2004                 27,669                               27,669  
Issuance of options to directors and committee chairmen for services rendered in October 2004                     54,582                               54,582  
Net loss attributable to noncontrolling interest                                             (9,774 )     (9,774 )
Comprehensive Income (Loss)                                                        
Net Loss attributable to CardioGenics Holdings Inc.                             (592,706 )                     (592,706 )
Other Comprehensive Income (Loss)                                                        
Currency Translation Adjustment                                     (6,136 )             (6,136 )
Total Comprehensive Income (Loss)                             (592,706 )     (6,136 )             (598,842 )
Balance at October 31, 2004     22,096,417     $ 222     $ 1,683,485     $ (1,426,548 )   $ 10,123     $ (19,786 )   $ 247,496  

 

See accompanying notes to consolidated financial statements. 

F-8
 

 

CardioGenics Holdings Inc.
(A Development Stage Company)
Consolidated Statements of Changes in Equity (Deficiency)
For the year ended October 31, 2011

 

                      Deficit                    
                      Accumulated                    
                      During     Accumulated            
                Additional     the     Other           Total  
    Common Stock     Paid-in     Development     Comprehensive     Noncontrolling     Equity  
    Shares     Amount     Capital     Stage     Loss     Interest     (Deficiency)  
                                           
Balance November 1, 2004     22,096,417     $ 222     $ 1,683,485     $ (1,426,548 )   $ 10,123     $ (19,786 )   $ 247,496  
Issuance of common shares as employee compensation November 2004, $.04     9,431             3,760                               3,760  
Issuance of common shares as employee compensation December 2004, $.04     9,431             3,692                               3,692  
Issuance of common shares as employee compensation January 2005, $.04     9,431             3,674                               3,674  
Issuance of common shares as employee compensation February 2005, $.04     9,431             3,629                               3,629  
Issuance of common shares as employee compensation March 2005, $.04     9,431             3,701                               3,701  
Issuance of common shares as employee compensation April 2005, $.04     9,431             3,641                               3,641  
Issuance of common shares as employee compensation May 2005, $.04     9,431             3,584                               3,584  
Issuance of common shares as employee compensation June 2005, $.04     9,431             3,628                               3,628  
Issuance of common shares as employee compensation July 2005, $.04     9,431             3,680                               3,680  
Issuance of common shares as employee compensation August 2005, $.04     9,431             3,737                               3,737  
Issuance of common shares as employee compensation September 2005, $.04     9,431             3,821                               3,821  
Issuance of common shares as employee compensation October 2005, $.04     9,431             3,822                               3,822  
Issuance of stock options in exchange for services rendered October 2005                 33,973                               33,973  
Net loss attributtable to noncontolling interest                                             (11,195 )     (11,195 )
Comprehensive Income (Loss)                                                        
Net Loss attributable to CardioGenics Holdings Inc.                             (682,408 )                     (682,408 )
Other Comprehensive Income (Loss)                                                        
Currency Translation Adjustment                                     (13,288 )             (13,288 )
Total Comprehensive Income (Loss)                             (682,408 )     (13,288 )             (695,696 )
Balance at October 31, 2005     22,209,589     $ 222     $ 1,761,827     $ (2,108,956 )   $ (3,165 )   $ (30,981 )   $ (381,053 )

 

                      Deficit                    
                      Accumulated                    
                      During     Accumulated            
                Additional     the     Other           Total  
    Common Stock     Paid-in     Development     Comprehensive     Noncontrolling     Equity  
    Shares     Amount     Capital     Stage     Loss     Interest     (Deficiency)  
                                           
Balance November 1, 2005     22,209,589     $ 222     $ 1,761,827     $ (2,108,956 )   $ (3,165 )   $ (30,981 )   $ (381,053 )
Issuance of common shares as employee compensation November 2005, $.04     10,478             4,232                               4,232  
Issuance of common shares in exchange for services rendered December 2005, $.04     10,478             4,305                               4,305  
Issuance of common shares in exchange for services rendered January 2006, $.04     10,478             4,321                               4,321  
Issuance of stock options in exchange for services rendered October 2006                 2,658                               2,658  
Net loss attributable to noncontrolling interest                                             (8,561 )     (8,561 )
Comprehensive Income (Loss)                                                        
Net Loss attributable to CardioGenics Holdings Inc.                             (522,532 )                     (522,532 )
Other Comprehensive Income (Loss)                                                        
Currency Translation Adjustment                                     (25,688 )             (25,688 )
Total Comprehensive Income (Loss)                             (522,532 )     (25,688 )             (548,220 )
Balance at October 31, 2006     22,241,023     $ 222     $ 1,777,343     $ (2,631,488 )   $ (28,853 )   $ (39,542 )   $ (922,318 )

 

See accompanying notes to consolidated financial statements. 

F-9
 

 

CardioGenics Holdings Inc.
(A Development Stage Company)
Consolidated Statements of Changes in Equity (Deficiency)
For the year ended October 31, 2011

 

                      Deficit                    
                      Accumulated                    
                      During     Accumulated            
                Additional     the     Other           Total  
    Common Stock     Paid-in     Development     Comprehensive     Noncontrolling     Equity  
    Shares     Amount     Capital     Stage     Loss     Interest     (Deficiency)  
                                           
Balance November 1, 2006     22,241,023     $ 222     $ 1,777,343     $ (2,631,488 )   $ (28,853 )   $ (39,542 )   $ (922,318 )
Incremental increase in fair value of warrants in conjunction with re-structuring of debentures, April 2007                     44,096                               44,096  
Net loss attributable to noncontrolling interest                                             (4,972 )     (4,972 )
Comprehensive Income (Loss)                                                        
Net Loss attributable to CardioGenics Holdings Inc.                             (303,477 )                     (303,477 )
Other Comprehensive Income (Loss)                                                        
Currency Translation Adjustment                                     (184,432 )             (184,432 )
Total Comprehensive Income (Loss)                             (303,477 )     (184,432 )             (487,909 )
Balance at October 31, 2007     22,241,023     $ 222     $ 1,821,439     $ (2,934,965 )   $ (213,285 )   $ (44,514 )   $ (1,371,103 )

 

                      Deficit                    
                      Accumulated                    
                      During     Accumulated            
                Additional     the     Other           Total  
    Common Stock     Paid-in     Development     Comprehensive     Noncontrolling     Equity  
    Shares     Amount     Capital     Stage     Loss     Interest     (Deficiency)  
                                           
Balance November 1, 2007     22,241,023     $ 222     $ 1,821,439     $ (2,934,965 )   $ (213,285 )   $ (44,514 )   $ (1,371,103 )
Issuance of warrants in conjunction with re-structuring of debentures October 2008                     231,580                               231,580  
Net loss attributable to noncontrolling interest                                             (21,813 )     (21,813 )
Comprehensive Income (Loss)